

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 June 2005 (23.06.2005)

PCT

(10) International Publication Number
WO 2005/055998 A1

(51) International Patent Classification⁷: **A61K 31/205**,
31/195

(21) International Application Number:
PCT/US2004/040440

(22) International Filing Date: 3 December 2004 (03.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/526,770 4 December 2003 (04.12.2003) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KIKKAWA, Hideo**
[JP/JP]; Tsukuba Research Laboratories, 43 Wadai, Tsukuba-shi, Ibaraki (JP). **KINOSHITA, Mine** [JP/JP]; Tsukuba Research Laboratories, 43 Wadai, Tsukuba-shi, Ibaraki (JP). **KURUSU, Osamu** [JP/JP]; Tsukuba Research Laboratories, 43 Wadai, Tsukuba-shi, Ibaraki (JP).

(74) Agents: **HAN, William, T.** et al.; GlaxoSmithKline, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS OF TREATMENT WITH LXR AGONISTS

(57) Abstract: The present invention relates generally to the use of LXR agonists in the prevention and/or treatment of eosinophilia or IL-13 overproduction, or diseases arising from eosinophilia or IL-13 production, such as allergy or asthma.



WO 2005/055998 A1

METHODS OF TREATMENT WITH LXR AGONISTS

FIELD OF THE INVENTION

5 The present invention relates generally to the use of LXR agonists in the prevention and/or treatment of eosinophilia or IL-13 overproduction, or diseases arising from eosinophilia or IL-13 production.

BACKGROUND OF THE INVENTION

10 LXR α and LXR β (collectively LXR) are nuclear hormone receptors that regulate the metabolism of several important lipids, including cholesterol (1). The nucleotide and amino acid sequences of LXR α are shown in Tables 1 and 2 (SEQ ID NOs:1 and 2), respectively. The nucleotide and amino acid sequences of LXR β are shown in Tables 3 and 4 (SEQ ID NOs:3
15 and 4), respectively. The LXRs regulate the expression of target genes by binding to short stretches of DNA, termed LXR response elements (LXREs), as heterodimers with the retinoid X receptors (RXR)(2-5). LXREs have been identified in the regulatory regions of a number of genes involved in cholesterol homeostasis including CYP7A1 (6), which catalyses the first and rate-limiting step in bile acid biosynthesis, the cholesterol ester transport protein (7), the
20 transcription factor SREBP-1C (8,9), and apolipoprotein E (apoE)(10). LXREs have also been identified in the genes encoding the ATP binding cassette transporters (ABC) A1 and G1(11-15), which mediate the efflux of phospholipids and cholesterol from macrophages, intestinal enterocytes and other cell types.

25 Currently, patients with elevated levels of cholesterol are treated using the compounds that inhibit the body's endogenous cholesterol synthesis. As important components of the complex system that regulates cholesterol levels in the body, the LXRs have also been proposed as targets for the prophylaxis and treatment of hypercholesterolemia (raised levels of plasma cholesterol) and its associated atherosclerotic diseases.

30 Eosinophils are only a small minority of peripheral blood leucocytes and, in normal subjects, most are found in the tissues of the lung and gastro-intestinal tract. Eosinophils leave the circulation when adhesion molecules on the cell surface are activated. Eosinophil production, maturation and survival are under the control of various cytokines and growth factors, including the interleukins and granulocyte macrophage colony stimulating factor.

Moderate to severe eosinophilia may be caused by the idiopathic hypereosinophilic syndrome (HES), but the commonest cause of eosinophilia worldwide is helminthic infection and, in industrialized nations, atopic disease.

5 Whatever the cause of the eosinophilia, in certain circumstances the eosinophils
produce damage to various organs by activation of eosinophils, thrombotic events,
release of eosinophilic granule contents and deposition of eosinophil proteins. There
are three categories of blood eosinophilia which are: 1. Reactive (non-clonal)
eosinophilia (asthma and allergies, respiratory diseases, cytokine infusions,
vasculitides, non-haematological malignant diseases, drug reactions and connective
10 tissue diseases.) 2. Clonal disorders of the bone marrow associated with eosinophilia
(acute and chronic eosinophilic leukemia, chronic myeloid leukemia, polycythaemia
rubra vera, essential thrombocythaemia, acute myeloid leukemia, chromosome 16
variants, the 8p11 myeloproliferative syndrome and T lymphoblastic lymphoma with
eosinophilia, acute lymphoblastic leukaemia, myelodysplastic disorders with
15 eosinophilia, systemic mastocytosis, and acute lymphoblastic leukemia). 3.
Hypereosinophilic syndrome (after exclusion of the above two categories, patients with
persistent, unexplained eosinophilia fall into the category of hypereosinophilic
syndrome). Sometimes, in the absence of blood eosinophilia, eosinophils accumulate
in specific organs (eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic
20 fasciitis, eosinophilic pancreatitis, eosinophilic synovitis, eosinophilic oesophagitis,
eosinophilic ascites and eosinophilic gastroenteritis).

On the other hand, interleukin (IL)-13 is a T helper 2 (Th2) cytokine family. IL-
13 shares a number of structural characteristics with IL-4, and appears to have certain
overlapping biological activities. IL-4 and IL-13 production is restricted to activated T
25 lymphocytes, especially Th2 cells, mast cells and basophils. IL-13 production has also
been demonstrated in dendritic cells and natural killer cells. IL-13 induces up-
regulation of MHC class II antigens in monocytes and macrophages. IL-13 also up-
regulates several members of the integrin superfamily (e.g. adhesion molecules), which
probably contributes to enhanced extravasation, mobility and trafficking of these cells.
30 IL-13 has been shown to support Th2 cell development, to induce human B-cells to
undergo Ig isotype switching to IgE and to regulate inflammatory responses by
suppressing tumour necrosis factor- α and IL-1 expression from monocytes and
macrophages. Neutralization of IL-13 in experimental asthma attenuated airway
hyperresponsiveness, eosinophil recruitment, and mucus overproduction. Moreover, IL-
35 13 deficient mice exhibited diminished accumulation of eosinophils and chronic
inflammatory cells, as well as reduced subepithelial fibrosis, epithelial hypertrophy and

mucous cell hyperplasia in a mouse model of chronic asthma. Neutralization of IL-13 attenuated bleomycin-induced pulmonary fibrosis in mice. An IL-13 inhibitor reduced hepatic fibrosis in schistosoma-infected mice.

5 The present invention relates to the new use of LXR agonists for treating or preventing eosinophilia or IL-13 overproduction, or diseases caused by eosinophilia or overproduction of IL-13, such as asthma or allergy (for example, allergic rhinitis).

SUMMARY OF THE INVENTION

10 In one aspect, the present invention provides a method of treating or preventing in a mammal eosinophilia or IL-13 overproduction, or diseases caused by eosinophilia or overproduction of IL-13, such as asthma or allergy (for example allergic rhinitis); comprising, administering a therapeutically effective amount of LXR agonist, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

15 In another aspect, the present invention provides a method of treating or preventing asthma or allergy (for example allergic rhinitis); comprising, administering a therapeutically effective amount of LXR agonist, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

20 In further aspect, the invention also relates to a pharmaceutical composition for treating or preventing in a mammal eosinophilia or IL-13 overproduction, or diseases caused by eosinophilia or overproduction of IL-13, such as asthma or allergy (for example allergic rhinitis); comprising a therapeutically effective amount of LXR agonist, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier.

25 Yet in a further aspect, the present invention relates to the use of a LXR agonist in the preparation of a medicament for treating or preventing in a mammal eosinophilia or IL-13 overproduction, or diseases caused by eosinophilia or overproduction of IL-13, such as asthma or allergy (for example allergic rhinitis).

30 DETAILED DESCRIPTION OF THE INVENTION

Table 1 shows the nucleotide sequence of human LXR α (SEQ ID NO:1) from Genebank, accession NM_005693.

35 Table 2 shows the deduced amino acid sequence of human LXR α (SEQ ID NO:2) from Genebank accession NP_005684.

Table 3 shows the nucleotide sequence of human LXR β from Genebank accession (SEQ ID NO:3) from Genbank accession XM_046419.

Table 4 shows the deduced amino acid sequence of human LXR β (SEQ ID NO:4) from Genebank accession XP_046419.

5 The term "LXR agonist" means any compound that enhances the biological activities of LXR α and/or LXR β . LXR agonists are well known. Preferred LXR agonists of the present invention are selected from compounds of formulas (I), (II), (III), (IV), and (V). The compounds of formulas (I), (II), (III), (IV), and (V) are described in more detail below. Other examples of LXR agonists which form part of instant invention are described in:

10

WO2002090375 published November 14, 2002;

WO2002058532 published August 1, 2002;

WO200211708 published February 14, 2002;

WO200160818 published August 23, 2001;

15

WO200115676 published March 8, 2001;

WO200103705 published January 18, 2001; and

WO2000666111 published November 9, 2000.


20 As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the
25 rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.

As used herein, the term "physiologically functional derivative" refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example, an ester or an amide, which upon administration to a mammal is capable of providing (directly or
30 indirectly) a compound of the present invention or an active metabolite thereof. Such derivatives are clear to those skilled in the art, without undue experimentation, and with reference to the teaching of Burger's Medicinal Chemistry And Drug Discovery, 5th Edition, Vol 1: Principles and Practice, which is incorporated herein by reference to the extent that it teaches physiologically functional derivatives.

35 As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited

to, water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include, without limitation, water, ethanol and acetic acid. Most preferably the solvent used is water.

International Patent Application WO 00/54759 (Tularik Inc. US) discloses compounds
5 of formula (I):



(I)

wherein:

Ar represents an aryl group; R¹ is –

10 OH, -O-(C₁-C₇)alkyl, -OC(O)-(C₁-C₇)alkyl, -O-(C₁-C₇)heteroalkyl, -OC(O)-(C₁-C₇)heteroalkyl, -CO₂H, -NH₂, -NH(C₁-C₇)alkyl, -N((C₁-C₇)alkyl)₂ or –
NH-S(O)₂-(C₁-C₅)alkyl;

R² is (C₁-C₇)alkyl, (C₁-C₇)heteroalkyl, aryl and aryl(C₁-C₇)alkyl;

X¹, X², X³, X⁴, X⁵ and X⁶ are each independently H, (C₁-C₅)alkyl, (C₁-C₅)heteroalkyl, F or
15 Cl, with the proviso that no more than three of X¹ through X⁶ are H, (C₁-C₅)alkyl or (C₁-C₅)heteroalkyl; and

Y is -N(R¹²)S(O)_m-, -N(R¹²)S(O)_mN(R¹³)-, -N(R¹²)C(O)-, –

N(R¹²)C(O)N(R¹³)-, -N(R¹²)C(S)- or -N(R¹²)C(O)O-, wherein R¹² and R¹³ are
20 each independently hydrogen, (C₁-C₇)aryl, (C₁-C₇)heteroalkyl, aryl and aryl(C₁-C₇)alkyl, and optionally when Y is –

N(R¹²)S(O)_m- or -N(R¹²)S(O)_mN(R¹³)-, R¹² forms a five, six or seven-membered ring fused to Ar or to R² through covalent attachment to Ar or R², respectively. In the above Y groups, the subscript m is an integer of from 1 to 2,

as being useful as agonists of LXR and their use in pharmaceutical formulations to reverse
25 cholesterol transport and treat atherosclerotic cardiovascular diseases and related diseases.

With respect to the compounds of formula (I) the term "alkyl", by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multi-radicals, having the number of carbons designated (*i.e.*, C₁₋₁₀ means one to ten carbons). Examples of saturated hydrocarbon radicals
30 include groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one

or more double bonds or triple bonds. Examples of unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butylnyl, and the higher homologs and isomers. The term "alkyl", unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below as "cycloalkyl" and "alkylene". The term "alkylene" by itself or as part of another substituent means a divalent radical derived from alkane, as exemplified by $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$.

Typically, an alkyl group will have from 1 to 24 carbon atoms, with those having 10 or fewer carbon atoms being preferred. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms, preferably four or fewer carbon atoms.

The term "alkoxy", employed alone or in combination with other terms means, unless otherwise stated, an alkyl group, as defined above, connected to the remainder of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy, and the higher homologs and isomers.

The term "heteroalkyl", by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si, S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quarternized. The heteroatom(s) O, N and S may be placed at any position of the heteroalkyl group except for the position at which the alkyl group is attached to the remainder of the molecule. Examples include $-\text{CH}_2\text{-CH}_2\text{-O-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-NH-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-N(CH}_3\text{)}$, $-\text{CH}_2\text{-S-CH}_2\text{-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-S(O)-CH}_3$, $-\text{CH}_2\text{-CH}_2\text{-S(O)}_2\text{-CH=CH-O-CH}_3$, $-\text{Si(CH}_3\text{)}_3$, $-\text{CH}_2\text{-CH=N-OCH}_3$, and $-\text{CH=CH-N(CH}_3\text{)-CH}_3$. Up to two heteroatoms may be consecutive, such as, for example, $-\text{CH}_2\text{-NH-OCH}_3$ and $-\text{CH}_2\text{-O-Si(CH}_3\text{)}_3$. Also included in the term "heteroalkyl" are those radicals described in more detail below as "heteroalkylene" and "heterocycloalkyl." The term "heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified by $-\text{CH}_2\text{-CH}_2\text{-S-CH}_2\text{-CH}_2-$ and $-\text{CH}_2\text{-S-CH}_2\text{-CH}_2\text{-NH-CH}_2-$. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini. Still further, for alkylene and heteroalkylene linking groups, as well as all other linking groups described herein, no specific orientation of the linking group is implied.

The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl" respectively. The terms "cycloalkyl" and "heterocycloalkyl" are also meant to include bicyclic, tricyclic and polycyclic versions thereof. Additionally, for heterocycloalkyl, a heteroatom may occupy the position at which the heterocyclyl is attached to the remainder of the molecule.

Examples of cycloalkyl include cyclopentyl, cyclohexyl, 1-cyclohexyl, 3-cyclohexyl, cyclopentyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, adamantyl, and the like. Example of heterocycloalkyl include 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, 1,4-diazabicyclo[2.2.2]oct-2-yl, 5 tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.

The terms "halo" or "halogen" by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine or iodine atom. Additionally, terms such as "fluoroalkyl", are meant to include monofluoroalkyl and polyfluoroalkyl.

10 The term "aryl", employed alone or in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) means, unless otherwise stated, an aromatic substituent which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently. The rings may each contain from zero to four heteroatoms selected from N, O and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally 15 quaternized. The aryl groups that contain heteroatoms may be referred to as "heteroaryl" and can be attached to the remainder of the molecule through a carbon atom or a heteroatom. Non-limiting examples of aryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 20 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinoliny, 5-isoquinoliny, 2-quinoxaliny, 5-quinoxaliny, 3-quinoliny, and 6-quinoliny. Substituents for each of the above noted aryl ring systems are selected from the group of acceptable substituents described below.

The terms "arylalkyl" and "arylheteroalkyl" are meant to include those radicals in 25 which an aryl group is attached to an aryl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) or a heteroalkyl group (e.g. phenoxymethyl, 2-pyridyloxymethyl, 1-naphthyloxy-3-propyl, and the like). The arylalkyl and arylheteroalkyl groups will typically contain from 1 to 3 aryl moieties attached to the alkyl or heteroalkyl portion by a covalent bond or by fusing the ring to, for example, a cycloalkyl or heterocycloalkyl group. For arylheteroalkyl groups, a heteroatom 30 can occupy the position at which the group is attached to the remainder of the molecule. For example, the term "arylheteroalkyl" is meant to include benzyloxy, 2-phenylethoxy, phenethylamine, and the like.

Each of the above terms (e.g., "alkyl", "heteroalkyl", "aryl" etc) is meant to include both substituted and unsubstituted forms of the indicated radical. Preferable substituents for 35 each type of radical are provided below.

Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be a variety of groups selected from: -OR, =O, =NR', N-OR', NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -CO₂R', -CONR'R'', OC(O)NR'R'', -NR''C(O)R', -NR''C(O)NR'R''', -NR''C(O)₂R',

5 NHC(NH₂)=NH, -NR'C(NH₂)=NH, -NH-, C(NH₂)=NR', S(O)R', -S(O)₂R', -S(O)₂NR'R'', -CN and -NO₂ in a number ranging from zero to (2N+1), where N is the total number of carbon atoms in such a radical. Preferably, substituted alkyl groups will have from one to six independently selected substituents, more preferably from one to four independently selected substituents, most preferably from one to three independently

10 selected substituents. In the substituents listed above, R', R'' and R''' each independently refer to hydrogen, unsubstituted (C₁₋₈)alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups or aryl-(C₁₋₄)alkyl groups. When R' and R'' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R'' is meant to include

15 1-pyrrolidinyl and 4-morpholinyl.

Similarly, substituents for the aryl groups are varied and selected from: -halogen, -OR', -OC(O)R', -NR'R'', -SR', -R', -CN, -NO₂, -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR''C(O)₂R', -NR''C(O)NR'R''', -NH-C(NH₂)=NH, -NR'C(NH₂)=NH, -NH-C(NH₂)=NR', -SOR', -S(O)₂R', -S(O)₂NR'R'', -N₃, -CH(Ph)₂, perfluor(C₁₋₄)alkoxy, and

20 perfluoro(C₁₋₄)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R' and R'' are independently selected from hydrogen, (C₁₋₈)alkyl and heteroalkyl, unsubstituted aryl, (unsubstituted aryl)-(C₁₋₄)alkyl, and (unsubstituted aryl)oxy-(C₁₋₄)alkyl. Preferably, substituted aryl groups will have from one to four independently selected substituents, more preferably from one to three independently

25 selected substituents, most preferably from one to two independently selected substituents.

Two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CH₂)_q-U-, wherein T and U are independently -NH-, -O-, CH₂ or a single bond, and q is an integer of from 0 to 2. Alternatively, two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of


30 formula -A-(CH₂)_r-B-, wherein A and B are independently -CH₂-, -O-, -NH-, S-, -S(O)-, -S(O)₂-, -S(O)₂NR'- or a single bond, and r is an integer of from 1 to 3. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula -(CH₂)_s-X-(CH₂)_t-, where s and t are integers of

35 from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O)₂-, or -S(O)₂NR'-. The substituent R' in -NR'- and S(O)₂NR'- selected from hydrogen or unsubstituted (C₁₋₆)alkyl.

The term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).

One particularly preferred LXR agonist of the present invention is Compound A within the scope of compounds of formula (I).

5




Compound A

Compound A is described as Example 12 of WO 00/54759.

10

Compounds of formula (I) can be prepared using readily available starting materials or known intermediates. WO 00/54759 describes a number of possible synthetic routes for the production of such compounds, such as those depicted in scheme 1.



Scheme 1


15

As shown in Scheme 1, aniline (i) (as representative of substituted anilines and other arylamines) can be alkylated, acylated or arylated (general addition of R group) to form (ii), or the aromatic ring can be derivatized with, for example, hexafluoroacetone to form (iii). Treatment of (iii) with an appropriate alkylating group, acylating group or arylating group

provides (iv), which can be sulfonylated with, for example, an appropriate sulfonyl halide to form (vi). Alternatively, the aniline derivative can be sulfonylated to form (v), which can then be alkylated or acylated to form compounds of formula (vi).

Other compounds of formula (I) can be formed by treating the substituted aniline (iv) (or iii), with reagents suitable for the formation of amides (vii), carbamates (viii) and ureas (ix). Various reagents are useful in the above scheme and can be found in, for example March, Advanced Organic Chemistry 4th ed. John Wiley & Sons, New York NY (1992)

International Patent Application PCT/US01/27622 (SmithKline Beecham plc) discloses compounds of formula (II):



wherein:

X is OH or NH₂;

p is 0-6;

each R¹ and R² are the same or different and are each independently selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₁₋₈thioalkyl;

Z is CH or N;

when Z is CH, k is 0-4;

when Z is N, k is 0-3;

each R³ is the same or different and is independently selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, -S(O)_aR⁶, -NR⁷R⁸, -COR⁶, COOR⁶, R¹⁰COOR⁶, OR¹⁰COOR⁶, CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, 5-6 membered heterocycle, nitro, and cyano;

a is 0, 1 or 2;

R⁶ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₂₋₈alkenyl;

each R⁷ and R⁸ are the same or different and are each independently selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl, C₃₋₈alkynyl;

R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸;

R¹⁰ is C₁₋₈alkyl;

n is 2-8;

q is 0 or 1;

R⁴ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkenyl, and alkenyloxy;

Ring A is selected from the group consisting of C₃₋₈cycloalkyl, aryl, 4-8 membered heterocycle, and 5-6 membered heteroaryl;

each ring B is the same or different and is independently selected from the group consisting of C₃₋₈cycloalkyl and aryl,

- 5 as being useful as agonists of LXR and their use in pharmaceutical formulations to reverse cholesterol transport and treat atherosclerotic cardiovascular diseases and related diseases.

With respect to compounds of formula (II) the term "alkyl" refers to aliphatic straight or branched saturated hydrocarbon chains containing the specified number of carbon atoms. Examples of "alkyl" groups as used herein include but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, octyl and the like. The term "alkyl" also refers to substituted alkyl wherein the substituents are selected from the group consisting of halo, -OR⁷ and -SR⁷, where R⁷ is H or C₁₋₈alkyl. This definition of "alkyl" is also applicable to terms such as "thioalkyl" which incorporate the "alkyl" term. Thus, a "thioalkyl" as used herein refers to the group S-Ra where Ra is "alkyl" as defined.

- 15 The term "halo" refers to any halogen atom ie., fluorine, chlorine, bromine or iodine.

The term "alkenyl" refers to an aliphatic straight or branched unsaturated hydrocarbon chain containing at least one and up to three carbon-carbon double bonds. Examples of "alkenyl" groups as used herein include, but are not limited to, ethenyl and propenyl. The term "alkenyl" also refers to substituted alkenyl wherein the substituents are selected from the group consisting of halo, -OR⁷ and -SR⁷, where R⁷ is H or C₁₋₈alkyl.

The term "alkoxy" refers to a group O-Ra where Ra is "alkyl" as defined above.

The term "alkenyloxy" refers to a group O-Rb where Rb is "alkenyl" as defined above.

The term "cycloalkyl" refers to a non-aromatic carbocyclic ring having the specified number of carbon atoms and up to three carbon-carbon double bonds. "Cycloalkyl" includes by way of example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and bicyclic cycloalkyl groups such as bicycloheptane and bicyclo(2.2.1)heptene. The term "cycloalkyl" also refers to substituted cycloalkyl wherein the ring bears one or more substituents selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano, wherein a is 0, 1 or 2; R⁶ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₂₋₈alkenyl; each R⁷ and R⁸ is the same or different and is independently selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl and C₃₋₈alkynyl; R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸; and R¹⁰ is C₁₋₈alkyl. As will be appreciated by those skilled in the art, the number of possible substituents on the cycloalkyl ring will depend upon the size of ring. In one preferred embodiment, the cycloalkyl is a cyclohexyl which may be substituted as described above.

The term "aryl" refers to aromatic groups selected from the group consisting of phenyl, 1-naphthyl and 2-naphthyl. The term "aryl" also refers to substituted aryl wherein the phenyl or naphthyl ring bears one or more substituents selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano, wherein a is 0, 1 or 2; R⁶ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₂₋₈alkenyl; each R⁷ and R⁸ is the same or different and is independently selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl and C₃₋₈alkynyl; R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸; and R¹⁰ is C₁₋₈alkyl. As will be appreciated by those skilled in the art, the number of possible substituents on the aryl ring will depend upon the size of ring. For example, when the aryl ring is phenyl, the aryl ring may have up to 5 substituents selected from the foregoing list. One skilled in the art will readily be able to determine the maximum number of possible substituents for a 1-naphthyl or 2-naphthyl ring. A preferred aryl ring according to formula (II) is phenyl, which may be substituted as described above.


The term "heterocycle" refers to a monocyclic saturated or unsaturated non-aromatic carbocyclic rings and fused bicyclic non-aromatic carbocyclic rings, having the specified number of members in the ring and containing 1, 2 or 3 heteroatoms selected from N, O and S. Examples of particular heterocyclic groups include but are not limited to tetrahydrofuran, dihydropyran, tetrahydropyran, pyran, oxetane, thietane, 1,4-dioxane, 1,3-dioxane, 1,3-dioxalane, piperidine, piperazine, tetrahydropyrimidine, pyrrolidine, morpholine, thiomorpholine, thiazolidine, oxazolidine, tetrahydrothiopyran, tetrahydrothiophene, and the like. The term "heterocycle" also refers to substituted heterocycles wherein the heterocyclic ring bears one or more substituents selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano, wherein a is 0, 1 or 2; R⁶ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₂₋₈alkenyl; each R⁷ and R⁸ is the same or different and is independently selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl and C₃₋₈alkynyl; and R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸; and R¹⁰ is C₁₋₈alkyl. As will be appreciated by those skilled in the art, the number of possible substituents on the heterocyclic ring will depend upon the size of ring. There are no restrictions on the positions of the optional substituents in the heterocycles. Thus, the term encompasses rings having a substituent attached to the ring through a heteroatom. One skilled in the art will readily be able to determine the maximum number and locations of possible substituents for any given heterocycle. A preferred heterocycle according to the invention is piperidine, which may be substituted as described above.

The term "heteroaryl" refers to aromatic monocyclic heterocyclic rings and aromatic fused bicyclic rings having the specified number of members in the ring, having at least one

aromatic ring and containing 1, 2 or 3 heteroatoms selected from N, O and S. Examples of particular heteroaryl groups include, but are not limited to, furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, benzofuran, benzothiophene, indole, and indazole. The term "heteroaryl" also refers to substituted heteroaryls wherein the heteroaryl ring bears one or more substituents selected from the group consisting of halo, -OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy, S(O)_aR⁶, -NR⁷R⁸, -COR⁶, -COOR⁶, -R¹⁰COOR⁶, -OR¹⁰COOR⁶, -CONR⁷R⁸, -OC(O)R⁹, -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, nitro, and cyano, wherein a is 0, 1 or 2; R⁶ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₂₋₈alkenyl; each R⁷ and R⁸ is the same or different and is independently selected from the group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl and C₃₋₈alkynyl; and R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸; and R¹⁰ is C₁₋₈alkyl. As will be appreciated by those skilled in the art, the number of possible substituents on the heteroaryl ring will depend upon the size of ring. There are no restrictions on the positions of the optional substituents in heteroaryls. Thus, the term encompasses rings having a substituent attached to the ring through a heteroatom. One skilled in the art will readily be able to determine the maximum number and locations of possible substituents for any given heteroaryl. A preferred heteroaryl according to the invention is pyridine, which may be substituted as described above.

The term "protecting group" refers to suitable protecting groups useful for the synthesis of compounds of formula (II) wherein X is OH. Suitable protecting groups are known to those skilled in the art and are described in *Protecting Groups in Organic Synthesis*, 3rd Edition, Greene, T. W.; Wuts, P. G. M. Eds.; John Wiley & Sons: NY, 1999. Examples of preferred protecting groups include but are not limited to methyl, ethyl, benzyl, substituted benzyl, and tert-butyl. In one embodiment the protecting group is methyl.

Another particularly preferred LXR agonist within the scope of formula (II) is Compound B of the formula




Compound B

5

described in Example 16 of PCT/US01/27622 (Smith Kline Beecham plc).

Compounds of formula (II) can be made according to any suitable method of organic chemistry. One method given in the specification is a solid phase synthesis process as depicted in Scheme 2.

10



Scheme 2


wherein X^0 is -O- or -NH-, SP is solid phase, R^{15} is H or a protecting group, and all other variables are as defined above in connection with the description of compounds of formula (II).

In general, the reaction proceeds by a) reacting a solid phase-bound amine (where X in the compound of formula (II) is NH_2) or alcohol (where X in the compound of formula (II) is OH) with a compound of formula (x) and a coupling agent to produce a solid phase-bound compound of formula (xi); b) in the embodiment wherein R^{15} is a protecting group, deprotecting the solid phase bound compound to prepare the compound of formula (xi); c) alkylating the solid phase-bound compound of formula (xi) with an alcohol of formula (xii) to produce a solid phase-bound compound of formula (xiii); d) reacting the solid-phase-bound compound of formula (xiii) with a compound of formula (xiv) to produce the solid-phase bound compound of formula (xv); and e) reacting the solid phase-bound compound of formula (xv) with a compound of formula (xvi) under reductive amination conditions to produce the solid

phase-bound compound of formula (II). The process may optionally further comprise the step of cleaving the solid phase-bound compound of formula (II) from the solid phase using conventional techniques such as treatment with mild acid.

Compounds of formula (II) are commercially available or can be prepared using conventional techniques such as those described in European Patent No. 303,742.

Compounds of formula (III) are described in U.S. Provisional Application Nos. 09/368,427, 60/368,425 and 60/368,426, each filed March 27, 2002:



wherein:

X is selected from C₁-C₈ alkyl, halo, -OR¹⁰, -NR¹⁴R¹⁵, nitro, cyano, -COOR¹⁰, -COR¹³, -OCOR¹³, -CONR¹⁴R¹⁵, -N(R¹⁷)COR¹³, -N(R¹⁷)CONR¹⁴R¹⁵, -N(R¹⁷)COOR¹³, -SO₃H, -SO₂NR¹⁴R¹⁵, -C(=NR¹⁷)NR¹⁴R¹⁵, -N(R¹⁷)SO₂R¹⁶, and a 5 or 6-membered heterocyclic group; or X and an adjacent R³, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety;

Z is CH, CR³ or N, wherein when Z is CH or CR³, k is 0-4 and t is 0 or 1, and when Z is N, k is 0-3 and t is 0;

Y is selected from -O-, -S-, -N(R¹⁰)-, and -C(R⁴)(R⁵)-;

W¹ is selected from C₁-C₆ alkyl, C₃-C₈ cycloalkyl, aryl and Het, wherein said C₁-C₈ alkyl, C₃-C₈ cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-CO₂R¹⁰, -C₀-C₆ alkyl-C(O)SR¹⁰, -C₀-C₆ alkyl-CONR¹¹R¹², -C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-NR¹¹R¹², -C₀-C₆ alkyl-SR¹⁰, -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-SO₃H, -C₀-C₆ alkyl-SO₂NR¹¹R¹², -C₀-C₆ alkyl-SO₂R¹⁰, -C₀-C₆ alkyl-SOR¹³, -C₀-C₆ alkyl-OCOR¹³, -C₀-C₆ alkyl-OC(O)NR¹¹R¹², -C₀-C₆ alkyl-OC(O)OR¹³, -C₀-C₆ alkyl-NR¹¹C(O)OR¹³, -C₀-C₆ alkyl-NR¹¹C(O)NR¹¹R¹², and -C₀-C₆ alkyl-NR¹¹COR¹³, where said C₁-C₆ alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W² is selected from H, halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -C₀-C₆ alkyl-NR¹¹R¹², -C₀-C₆ alkyl-SR¹⁰, -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-CO₂R¹⁰,

-C₀-C₆ alkyl-C(O)SR¹⁰, -C₀-C₆ alkyl-CONR¹¹R¹², -C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-OCOR¹³,
 -C₀-C₆ alkyl-OCONR¹¹R¹², -C₀-C₆ alkyl-NR¹¹CONR¹¹R¹², -C₀-C₆ alkyl-NR¹¹COR¹³,
 -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl, wherein said C₁-C₆ alkyl
 is optionally unsubstituted or substituted by one or more halo substituents, and wherein the
 5 C₃-C₇ cycloalkyl, Ar and Het moieties of said -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and
 -C₀-C₆ alkyl-C₃-C₇ cycloalkyl are optionally unsubstituted or substituted with one or more
 groups independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl,
 C₃-C₆ alkynyl, -C₀-C₆ alkyl-CO₂R¹⁰, -C₀-C₆ alkyl-C(O)SR¹⁰, -C₀-C₆ alkyl-CONR¹¹R¹²,
 -C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-NR¹¹R¹², -C₀-C₆ alkyl-SR¹⁰, -C₀-C₆ alkyl-OR¹⁰,
 10 -C₀-C₆ alkyl-SO₃H, -C₀-C₆ alkyl-SO₂NR¹¹R¹², -C₀-C₆ alkyl-SO₂R¹⁰, -C₀-C₆ alkyl-SOR¹³,
 -C₀-C₆ alkyl-OCOR¹³, -C₀-C₆ alkyl-OC(O)NR¹¹R¹², -C₀-C₆ alkyl-OC(O)OR¹³,
 -C₀-C₆ alkyl-NR¹¹C(O)OR¹³, -C₀-C₆ alkyl-NR¹¹C(O)NR¹¹R¹², and -C₀-C₆ alkyl-NR¹¹COR¹³,
 where said C₁-C₆ alkyl, is optionally unsubstituted or substituted by one or more halo
 substituents;

15 W³ is selected from the group consisting of: H, halo, C₁-C₆ alkyl, -C₀-C₆ alkyl-NR¹¹R¹²,
 -C₀-C₆ alkyl-SR¹⁰, -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-CO₂R¹⁰, -C₀-C₆ alkyl-C(O)SR¹⁰,
 -C₀-C₆ alkyl-CONR¹¹R¹², -C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-OCOR¹³,
 -C₀-C₆ alkyl-OCONR¹¹R¹², -C₀-C₆ alkyl-NR¹¹CONR¹¹R¹², -C₀-C₆ alkyl-NR¹¹COR¹³,
 -C₀-C₆ alkyl-Het, -C₁-C₆ alkyl-Ar and -C₁-C₆ alkyl-C₃-C₇ cycloalkyl, wherein said C₁-C₆ alkyl
 20 is optionally unsubstituted or substituted by one or more halo substituents;

Q is selected from C₃-C₈ cycloalkyl, Ar and Het; wherein said C₃-C₈ cycloalkyl, Ar and
 Het are optionally unsubstituted or substituted with one or more groups independently selected
 from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-CO₂R¹⁰,
 -C₀-C₆ alkyl-C(O)SR¹⁰, -C₀-C₆ alkyl-CONR¹¹R¹², -C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-NR¹¹R¹²,
 25 -C₀-C₆ alkyl-SR¹⁰, -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-SO₃H, -C₀-C₆ alkyl-SO₂NR¹¹R¹²,
 -C₀-C₆ alkyl-SO₂R¹⁰, -C₀-C₆ alkyl-SOR¹³, -C₀-C₆ alkyl-OCOR¹³, -C₀-C₆ alkyl-OC(O)NR¹¹R¹²,
 -C₀-C₆ alkyl-OC(O)OR¹³, -C₀-C₆ alkyl-NR¹¹C(O)OR¹³, -C₀-C₆ alkyl-NR¹¹C(O)NR¹¹R¹², and
 -C₀-C₆ alkyl-NR¹¹COR¹³, where said C₁-C₆ alkyl is optionally unsubstituted or substituted by
 one or more halo substituents;

30 p is 0-8;
 n is 2-8;
 m is 0 or 1;
 q is 0 or 1;
 t is 0 or 1;

35 each R¹ and R² are independently selected from H, halo, C₁-C₆ alkyl, C₃-C₆ alkenyl,
 C₃-C₆ alkynyl, -C₀-C₆ alkyl-NR¹¹R¹², -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-SR¹⁰, -C₁-C₆ alkyl-Het,
 -C₁-C₆ alkyl-Ar and -C₁-C₆ alkyl-C₃-C₇ cycloalkyl, or R¹ and R² together with the carbon to

which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O, and S, where any of said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R³ is the same or different and is independently selected from halo, cyano, nitro,
 5 C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het,
 -C₀-C₆ alkyl-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-CO₂R¹⁰, -C₀-C₆ alkyl-C(O)SR¹⁰,
 -C₀-C₆ alkyl-CONR¹¹R¹², -C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-NR¹¹R¹², -C₀-C₆ alkyl-SR¹⁰,
 -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-SO₃H, -C₀-C₆ alkyl-SO₂NR¹¹R¹², -C₀-C₆ alkyl-SO₂R¹⁰,
 -C₀-C₆ alkyl-SOR¹³, -C₀-C₆ alkyl-OCOR¹³, -C₀-C₆ alkyl-OC(O)NR¹¹R¹²,
 10 -C₀-C₆ alkyl-OC(O)OR¹³, -C₀-C₆ alkyl-NR¹¹C(O)OR¹³, -C₀-C₆ alkyl-NR¹¹C(O)NR¹¹R¹², and
 -C₀-C₆ alkyl-NR¹¹COR¹³, wherein said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R⁴ and R⁵ is independently selected from H, halo, C₁-C₆ alkyl, -C₀-C₆ alkyl-Het,
 -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;
 15 R⁶ and R⁷ are each independently selected from H, halo, C₁-C₆ alkyl, -C₀-C₆ alkyl-Het,
 -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

R⁸ and R⁹ are each independently selected from H, halo, C₁-C₆ alkyl, -C₀-C₆ alkyl-Het,
 -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

R¹⁰ is selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar,
 20 -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

each R¹¹ and each R¹² are independently selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl,
 C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl, or R¹¹ and
 R¹² together with the nitrogen to which they are attached form a 4-7 membered heterocyclic
 ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

R¹³ is selected from C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar,
 25 -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;


R¹⁴ and R¹⁵ are each independently selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl,
 C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-C₃-C₇ cycloalkyl,
 -C₀-C₆ alkyl-O-Ar, -C₀-C₆ alkyl-O-Het, -C₀-C₆ alkyl-O-C₃-C₇ cycloalkyl,
 30 -C₀-C₆ alkyl-S(O)_x-C₁-C₆ alkyl, -C₀-C₆ alkyl-S(O)_x-Ar, -C₀-C₆ alkyl-S(O)_x-Het,
 -C₀-C₆ alkyl-S(O)_x-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-NH-Het, -C₀-C₆ alkyl-NH-C₃-C₇ cycloalkyl,
 -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-Ar, -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-Het,
 -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and
 -C₀-C₆ alkyl-C₃-C₇ cycloalkyl, where x is 0, 1 or 2, or R¹⁴ and R¹⁵, together with the nitrogen to
 35 which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one
 or more additional heteroatoms selected from N, O, and S, wherein said C₁-C₆ alkyl is
 optionally substituted by one or more of the substituents independently selected from the group

- halo, -OH, -SH, -NH₂, -NH(unsubstituted C₁-C₆ alkyl), -N(unsubstituted C₁-C₆ alkyl)(unsubstituted C₁-C₆ alkyl), unsubstituted -OC₁-C₆ alkyl, -CO₂H, -CO₂(unsubstituted C₁-C₆ alkyl), -CONH₂, -CONH(unsubstituted C₁-C₆ alkyl), -CON(unsubstituted C₁-C₆ alkyl)(unsubstituted C₁-C₆ alkyl), -SO₃H, -SO₂NH₂, -SO₂NH(unsubstituted C₁-C₆ alkyl) and -SO₂N(unsubstituted C₁-C₆ alkyl)(unsubstituted C₁-C₆ alkyl);

R¹⁶ is C₁-C₆ alkyl, -C₀-C₆ alkyl-Ar or -C₀-C₆ alkyl-Het; and

R¹⁷ is H, C₁-C₆ alkyl, -C₀-C₆ alkyl-Ar or -C₀-C₆ alkyl-Het.

- 10 Compounds of formula (IV) are described in U.S. Provisional Application No. 60/368,415, filed March 27, 2002:



wherein:

X is CH or N;

- 15 Y is N(R¹⁰), O, or S, wherein t is 0 or 1 when Y is N(R¹⁰) or O, and t is 0 when Y is S;

U is selected from halo, -OR¹⁰, -NR¹⁴R¹⁵, nitro, cyano, -COOR¹⁰, -COR¹³, -OCOR¹³, -CONR¹⁴R¹⁵, -N(R¹⁴)COR¹³, -SO₃H, -SO₂NR¹⁴R¹⁵, -C(=NR¹⁷)NR¹⁴R¹⁵, -N(R¹⁴)SO₂R¹⁶, and a 5 or 6-membered heterocyclic group;

- 20 A is a phenyl fused ring moiety or a pyridyl fused ring moiety, wherein when A is a phenyl ring moiety, k is 0-3 and t is 0 or 1 and when A is a pyridyl ring moiety, k is 0-2 and t is 0;

W¹ is selected from C₃-C₈ cycloalkyl, aryl and Het, wherein said C₃-C₈ cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl,

- 25 -C₀-C₆ alkyl-CO₂R¹⁰, -C₀-C₆ alkyl-C(O)SR¹⁰, -C₀-C₆ alkyl-CONR¹¹R¹², -C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-NR¹¹R¹², -C₀-C₆ alkyl-SR¹⁰, -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-SO₃H, -C₀-C₆ alkyl-SO₂NR¹¹R¹², -C₀-C₆ alkyl-SO₂R¹⁰, -C₀-C₆ alkyl-SOR¹³, -C₀-C₆ alkyl-OCOR¹³, -C₀-C₆ alkyl-OC(O)NR¹¹R¹², -C₀-C₆ alkyl-OC(O)OR¹³, -C₀-C₆ alkyl-NR¹¹C(O)OR¹³,

$-C_0-C_6$ alkyl- $NR^{11}C(O)NR^{11}R^{12}$, and $-C_0-C_6$ alkyl- $NR^{11}COR^{13}$, where said C_1-C_6 alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

- W^2 is selected from H, halo, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl,
 $-C_0-C_6$ alkyl- $NR^{11}R^{12}$, $-C_0-C_6$ alkyl- SR^{10} , $-C_0-C_6$ alkyl- OR^{10} , $-C_0-C_6$ alkyl- CO_2R^{10} ,
 5 $-C_0-C_6$ alkyl- $C(O)SR^{10}$, $-C_0-C_6$ alkyl- $CONR^{11}R^{12}$, $-C_0-C_6$ alkyl- COR^{13} , $-C_0-C_6$ alkyl- $OCOR^{13}$,
 $-C_0-C_6$ alkyl- $OCONR^{11}R^{12}$, $-C_0-C_6$ alkyl- $NR^{11}CONR^{11}R^{12}$, $-C_0-C_6$ alkyl- $NR^{11}COR^{13}$,
 $-C_0-C_6$ alkyl-Het, $-C_0-C_6$ alkyl-Ar and $-C_0-C_6$ alkyl- C_3-C_7 cycloalkyl, wherein said C_1-C_6 alkyl
 is optionally unsubstituted or substituted by one or more halo substituents, and wherein the
 C_3-C_7 cycloalkyl, Ar and Het moieties of said $-C_0-C_6$ alkyl-Het, $-C_0-C_6$ alkyl-Ar and
 10 $-C_0-C_6$ alkyl- C_3-C_7 cycloalkyl are optionally unsubstituted or substituted with one or more
 groups independently selected from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl,
 C_3-C_6 alkynyl, $-C_0-C_6$ alkyl- CO_2R^{10} , $-C_0-C_6$ alkyl- $C(O)SR^{10}$, $-C_0-C_6$ alkyl- $CONR^{11}R^{12}$,
 $-C_0-C_6$ alkyl- COR^{13} , $-C_0-C_6$ alkyl- $NR^{11}R^{12}$, $-C_0-C_6$ alkyl- SR^{10} , $-C_0-C_6$ alkyl- OR^{10} ,
 $-C_0-C_6$ alkyl- SO_3H , $-C_0-C_6$ alkyl- $SO_2NR^{11}R^{12}$, $-C_0-C_6$ alkyl- SO_2R^{10} , $-C_0-C_6$ alkyl- SOR^{13} ,
 15 $-C_0-C_6$ alkyl- $OCOR^{13}$, $-C_0-C_6$ alkyl- $OC(O)NR^{11}R^{12}$, $-C_0-C_6$ alkyl- $OC(O)OR^{13}$,
 $-C_0-C_6$ alkyl- $NR^{11}C(O)OR^{13}$, $-C_0-C_6$ alkyl- $NR^{11}C(O)NR^{11}R^{12}$, and $-C_0-C_6$ alkyl- $NR^{11}COR^{13}$,
 where said C_1-C_6 alkyl, is optionally unsubstituted or substituted by one or more halo
 substituents;

- W^3 is selected from the group consisting of: H, halo, C_1-C_6 alkyl, $-C_0-C_6$ alkyl- $NR^{11}R^{12}$,
 20 $-C_0-C_6$ alkyl- SR^{10} , $-C_0-C_6$ alkyl- OR^{10} , $-C_0-C_6$ alkyl- CO_2R^{10} , $-C_0-C_6$ alkyl- $C(O)SR^{10}$,
 $-C_0-C_6$ alkyl- $CONR^{11}R^{12}$, $-C_0-C_6$ alkyl- COR^{13} , $-C_0-C_6$ alkyl- $OCOR^{13}$,
 $-C_0-C_6$ alkyl- $OCONR^{11}R^{12}$, $-C_0-C_6$ alkyl- $NR^{11}CONR^{11}R^{12}$, $-C_0-C_6$ alkyl- $NR^{11}COR^{13}$,
 $-C_0-C_6$ alkyl-Het, $-C_1-C_6$ alkyl-Ar and $-C_1-C_6$ alkyl- C_3-C_7 cycloalkyl, wherein said C_1-C_6 alkyl
 is optionally unsubstituted or substituted by one or more halo substituents;

- 25 Q is selected from C_3-C_8 cycloalkyl, Ar and Het; wherein said C_3-C_8 cycloalkyl, Ar and
 Het are optionally unsubstituted or substituted with one or more groups independently selected
 from halo, cyano, nitro, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, $-C_0-C_6$ alkyl- CO_2R^{10} ,
 $-C_0-C_6$ alkyl- $C(O)SR^{10}$, $-C_0-C_6$ alkyl- $CONR^{11}R^{12}$, $-C_0-C_6$ alkyl- COR^{13} , $-C_0-C_6$ alkyl- $NR^{11}R^{12}$,
 $-C_0-C_6$ alkyl- SR^{10} , $-C_0-C_6$ alkyl- OR^{10} , $-C_0-C_6$ alkyl- SO_3H , $-C_0-C_6$ alkyl- $SO_2NR^{11}R^{12}$,
 30 $-C_0-C_6$ alkyl- SO_2R^{10} , $-C_0-C_6$ alkyl- SOR^{13} , $-C_0-C_6$ alkyl- $OCOR^{13}$, $-C_0-C_6$ alkyl- $OC(O)NR^{11}R^{12}$,
 $-C_0-C_6$ alkyl- $OC(O)OR^{13}$, $-C_0-C_6$ alkyl- $NR^{11}C(O)OR^{13}$, $-C_0-C_6$ alkyl- $NR^{11}C(O)NR^{11}R^{12}$, and
 $-C_0-C_6$ alkyl- $NR^{11}COR^{13}$, where said C_1-C_6 alkyl is optionally unsubstituted or substituted by
 one or more halo substituents;

- p is 0-8;
 35 n is 2-8;
 m is 0 or 1;
 q is 0 or 1;

t is 0 or 1;

each R¹ and R² are independently selected from H, halo, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-NR¹¹R¹², -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-SR¹⁰, -C₁-C₆ alkyl-Het, -C₁-C₆ alkyl-Ar and -C₁-C₆ alkyl-C₃-C₇ cycloalkyl, or R¹ and R² together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O, and S, where said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R³ is the same or different and is independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-CO₂R¹⁰, -C₀-C₆ alkyl-C(O)SR¹⁰, -C₀-C₆ alkyl-CONR¹¹R¹², -C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-NR¹¹R¹², -C₀-C₆ alkyl-SR¹⁰, -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-SO₃H, -C₀-C₆ alkyl-SO₂NR¹¹R¹², -C₀-C₆ alkyl-SO₂R¹⁰, -C₀-C₆ alkyl-SOR¹³, -C₀-C₆ alkyl-OCOR¹³, -C₀-C₆ alkyl-OC(O)NR¹¹R¹², -C₀-C₆ alkyl-OC(O)OR¹³, -C₀-C₆ alkyl-NR¹¹C(O)OR¹³, -C₀-C₆ alkyl-NR¹¹C(O)NR¹¹R¹², and -C₀-C₆ alkyl-NR¹¹COR¹³, wherein said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R⁴ and R⁵ is independently selected from H, halo, C₁-C₆ alkyl, -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

R⁶ and R⁷ are each independently selected from H, halo, C₁-C₆ alkyl, -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

R⁸ and R⁹ are each independently selected from H, halo, C₁-C₆ alkyl, -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

R¹⁰ is selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

each R¹¹ and each R¹² are independently selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl, or R¹¹ and R¹² together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

R¹³ is selected from C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

R¹⁴ and R¹⁵ are each independently selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-O-Ar, -C₀-C₆ alkyl-O-Het, -C₀-C₆ alkyl-O-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-S(O)_x-C₁-C₆ alkyl, -C₀-C₆ alkyl-S(O)_x-Ar, -C₀-C₆ alkyl-S(O)_x-Het, -C₀-C₆ alkyl-S(O)_x-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-NH-Ar, -C₀-C₆ alkyl-NH-Het, -C₀-C₆ alkyl-NH-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-Ar, -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-Het, -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-C₃-C₇ cycloalkyl,

-C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl, where x is 0, 1 or 2, or R¹⁴ and R¹⁵, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C₁-C₆ alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH₂, -NH(unsubstituted C₁-C₆ alkyl), -N(unsubstituted C₁-C₆ alkyl)(unsubstituted C₁-C₆ alkyl), unsubstituted -OC₁-C₆ alkyl, -CO₂H, -CO₂(unsubstituted C₁-C₆ alkyl), -CONH₂, -CONH(unsubstituted C₁-C₆ alkyl), -CON(unsubstituted C₁-C₆ alkyl)(unsubstituted C₁-C₆ alkyl), -SO₃H, -SO₂NH₂, -SO₂NH(unsubstituted C₁-C₆ alkyl) and -SO₂N(unsubstituted C₁-C₆ alkyl)(unsubstituted C₁-C₆ alkyl);

R¹⁶ is C₁-C₆ alkyl, -C₀-C₆ alkyl-Ar or -C₀-C₆ alkyl-Het; and

R¹⁷ is H, C₁-C₆ alkyl, -C₀-C₆ alkyl-Ar or -C₀-C₆ alkyl-Het.



Unless otherwise provided, each alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl or Het (including any 3-5-membered, 4-7-membered or 5-7-membered carbocyclic or heterocyclic rings or ring moieties) in the compounds of formula (III) and (IV) is independently unsubstituted or substituted with one or more substituents defined hereinbelow.

In the compounds of formula (IV), group A is defined as a phenyl or a pyridyl fused ring moiety and is exemplified by the following:



Group A fused ring moiety:

20

phenyl:



pyridyl:



As used to define the compounds of formulas (III) or (IV), the term "alkyl" represents a straight-or branched-chain saturated hydrocarbon, containing 1 to 10 carbon atoms, unless otherwise provided, which may be unsubstituted or substituted by one or more of the substituents described below. Exemplary alkyls include, but are not limited to methyl (Me), ethyl (Et), n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, neopentyl and hexyl and structural isomers thereof. Any "alkyl" herein may be optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH₂, -NH(unsubstituted C₁-C₆ alkyl), -N(unsubstituted C₁-C₆ alkyl)(unsubstituted C₁-C₆ alkyl), unsubstituted -OC₁-C₆ alkyl, and -CO₂H.

When combined with another substituent term as used to define the compounds of formulas (III) or (IV) (e.g., aryl or cycloalkyl as in -alkyl-Ar or -alkyl-cycloalkyl), the "alkyl" term therein refers to an alkylene moiety, that is, an unsubstituted divalent straight-or branched-chain saturated hydrocarbon moiety, containing 1 to 10 carbon atoms, unless

otherwise provided. For example, the term "-C₀-C₆ alkyl-Ar", where C is 1-6 is intended to mean the radical -alkyl-aryl (e.g., -CH₂-aryl or -CH(CH₃)-aryl) and is represented by the bonding arrangement present in a benzyl group. The term "C₀ alkyl" in a moiety, such as -C₀-C₆ alkyl-Ar or -O-(C₀-C₆ alkyl)-Ar, provides for no alkyl/alkylene group being present in the moiety. Thus, when C is zero, -C₀-C₆ alkyl-Ar is equivalent to -Ar and -O-(C₀-C₆ alkyl)-Ar is equivalent to -O-Ar.

As used to define the compounds of formulas (III) or (IV), the term "alkenyl" represents a straight-or branched-chain hydrocarbon, containing 2 to 10 carbon atoms, unless otherwise provided, and one or more carbon-carbon double bonds. Alkenyl groups may be unsubstituted or substituted by one or more of the substituents described below. Exemplary alkenyls include, but are not limited ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, pentenyl and hexenyl and structural isomers thereof. Both cis (Z) and trans (E) isomers of each double bond that may be present in the compounds of formula (III) or (IV) are included within the scope of this definition. Any "alkenyl" herein may be optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH₂, -NH(unsubstituted C₁-C₆ alkyl), -N(unsubstituted C₁-C₆ alkyl)(unsubstituted C₁-C₆ alkyl), unsubstituted -OC₁-C₆ alkyl, and -CO₂H.

As used to define the compounds of formulas (III) or (IV), the term "alkynyl" represents a straight- or branched-chain hydrocarbon, containing 2 to 10 carbon atoms, unless otherwise provided, and one or more carbon-carbon triple bonds and, optionally, one or more carbon-carbon double bonds. Both cis (Z) and trans (E) isomers of each double bond that may be present in the compounds of formula (III) or (IV) are included within the scope of this definition. Exemplary alkynyls include, but are not limited ethynyl, propynyl (propargyl, isopropynyl), 1-butyne, 2-butyne, 3-butyne, pentynyl and hexynyl and structural isomers thereof. Any "alkynyl" herein may be optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH₂, -NH(unsubstituted C₁-C₆ alkyl), -N(unsubstituted C₁-C₆ alkyl)(unsubstituted C₁-C₆ alkyl), unsubstituted -OC₁-C₆ alkyl, and -CO₂H.

As used to define the compounds of formulas (III) or (IV), when an alkenyl or alkynyl group is a substituent on an oxygen, nitrogen or sulfur atom (e.g., as in oxy (-OR), thio (-SR), ester (-CO₂R or -C(O)SR), amino (-NRR) or amido (-CONRR) moieties and the like), it is understood that a double or triple bond of the alkenyl or alkynyl group is not located on carbons that are α,β to the oxygen, nitrogen or sulfur atom. Compounds containing ene-amino or enol-type moieties (-NR-CR=CR- or -O-CR=CR-) are not intended to be included within the scope of the definition of the compounds of formula (III) or (IV).

As used to define the compounds of formulas (III) or (IV), the term "cycloalkyl" represents a non-aromatic monocyclic, bicyclic, or tricyclic hydrocarbon containing from 3 to

10 carbon atoms which may be unsubstituted or substituted by one or more of the substituents described below and may be saturated or partially unsaturated. Exemplary cycloalkyls include monocyclic rings having from 3-7, preferably 3-6, carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl and
5 cycloheptyl. Any "cycloalkyl" herein may be optionally substituted by one or more of the substituents independently selected from the group halo, cyano, C₁-C₆ alkyl (which specifically includes C₁-C₆ haloalkyl, -C₀-C₆ alkyl-OH, -C₀-C₆ alkyl-SH and -C₀-C₆ alkyl-NR'R"), C₃-C₆ alkenyl, oxo, -OC₁-C₆alkyl, -OC₁-C₆ alkenyl, -C₀-C₆ alkyl-COR', -C₀-C₆ alkyl-CO₂R', -C₀-C₆ alkyl-CONR'R", -OC₀-C₆ alkyl-CO₂H, -OC₂-C₆ alkyl-NR'R", and
10 -C₀-C₆ alkyl-SO₂NR'R", wherein each R' and R" are independently selected from H or unsubstituted C₁-C₆ alkyl.

As used to define the compounds of formulas (III) or (IV), the terms "Ar" or "aryl" is used interchangeably at all occurrences mean a substituted or unsubstituted carbocyclic aromatic group, which may be optionally fused to another carbocyclic aromatic group moiety
15 or to a cycloalkyl group moiety, which may be optionally substituted or unsubstituted. Examples of suitable Ar or aryl groups include phenyl, naphthyl indenyl, 1-oxo-1*H*-indenyl and tetrahydronaphthyl. Any "Ar", "aryl" or "phenyl" herein may be optionally unsubstituted or substituted by one or more of the substituents independently selected from the group halo, cyano, C₁-C₆ alkyl (which specifically includes C₁-C₆ haloalkyl, -C₀-C₆ alkyl-OH,
20 -C₀-C₆ alkyl-SH and -C₀-C₆ alkyl-NR'R"), C₃-C₆ alkenyl, -OC₁-C₆alkyl, -OC₁-C₆ alkenyl, -C₀-C₆ alkyl-COR', -C₀-C₆ alkyl-CO₂R', -C₀-C₆ alkyl-CONR'R", -OC₀-C₆ alkyl-CO₂H, -OC₂-C₆ alkyl-NR'R", -C₀-C₆ alkyl-C(=NR')NR'R", and -C₀-C₆ alkyl-SO₂NR'R", wherein each R' and R" are independently selected from H or unsubstituted C₁-C₆ alkyl.

As used to define the compounds of formulas (III) or (IV), the term "Het" means a
25 stable 5- to 7-membered monocyclic, a stable 7- to 10-membered bicyclic, or a stable 11- to 18-membered tricyclic heterocyclic ring group, all of which are saturated, unsaturated or aromatic, and consist of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and which includes bicyclic and tricyclic rings containing one or more fused cycloalkyl, aryl (e.g., phenyl) or heteroaryl (aromatic Het) ring moieties. As used
30 herein the term "Het" is also intended to encompass heterocyclic groups containing nitrogen and/or sulfur where the nitrogen or sulfur heteroatoms are optionally oxidized or the nitrogen heteroatom is optionally quaternized. The heterocyclic group may be attached at any heteroatom or carbon atom that results in the creation of a stable structure. Any "Het" herein may be optionally unsubstituted or substituted by one or more of the substituents independently
35 selected from the group halo, cyano, C₁-C₆ alkyl (which specifically includes C₁-C₆ haloalkyl, -C₀-C₆ alkyl-OH, -C₀-C₆ alkyl-SH and -C₀-C₆ alkyl-NR'R"), C₃-C₆ alkenyl, oxo, -OC₁-C₆alkyl, -OC₁-C₆ alkenyl, -C₀-C₆ alkyl-COR', -C₀-C₆ alkyl-CO₂R', -C₀-C₆ alkyl-CONR'R",

-OC₀-C₆ alkyl-CO₂H, -OC₂-C₆ alkyl-NR'R", -C₀-C₆ alkyl-C(=NR')NR'R" and -C₀-C₆ alkyl-SO₂NR'R", wherein each R' and R" are independently selected from H or unsubstituted C₁-C₆ alkyl.

Examples of such heterocyclic groups include, but are not limited to piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepanyl, pyrrolyl, 4-piperidinyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, pyridinyl, pyrazinyl, oxazolidinyl, oxazolinyl, oxazolyl, isoxazolyl, morpholinyl, thiazolidinyl, thiazolinyl, thiazolyl, 1,3-benzodioxolyl (e.g., methylenedioxy-substituted phenyl), 1,4-benzodioxolyl, quinuclidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, benzoxazolyl, furyl, pyranal, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzoxazolyl, benzofuranyl, benzothienyl, dihydrobenzofuranyl, dihydrobenzothienyl, dihydroindolyl, tetrazolyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl, as well as triazolyl, thiadiazolyl, oxadiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyridazinyl, pyrimidinyl and triazinyl which are available by routine chemical synthesis and are stable.

Examples of the 4-7 membered heterocyclic rings useful in the compounds of formula (III) or (IV), include, but are not limited to azetidiny, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, azepanyl, pyrrolyl, 4-piperidinyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, pyridinyl, pyrazinyl, oxazolidinyl, oxazolinyl, oxazolyl, isoxazolyl, morpholinyl, thiazolidinyl, thiazolinyl, thiazolyl, furyl, pyranal, tetrahydrofuryl, tetrahydropyranyl, thienyl, tetrazolyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl, as well as triazolyl, thiadiazolyl, oxadiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyridazinyl, pyrimidinyl and triazinyl which are available by routine chemical synthesis and are stable. The 4-7 membered heterocyclic group may be optionally unsubstituted or substituted by one or more of the substituents independently selected from the group halo, cyano, C₁-C₆ alkyl (which specifically includes C₁-C₆ haloalkyl, -C₀-C₆ alkyl-OH, -C₀-C₆ alkyl-SH and -C₀-C₆ alkyl-NR'R"), C₃-C₆ alkenyl, oxo, -OC₁-C₆alkyl, -OC₁-C₆ alkenyl, -C₀-C₆ alkyl-COR', -C₀-C₆ alkyl-CO₂R', -C₀-C₆ alkyl-CONR'R", -OC₀-C₆ alkyl-CO₂H, -OC₂-C₆ alkyl-NR'R", -C₀-C₆ alkyl-C(=NR')NR'R" and -C₀-C₆ alkyl-SO₂NR'R", wherein each R' and R" are independently selected from H or unsubstituted C₁-C₆ alkyl.

Examples of 5 or 6 membered heterocyclic groups include, but are not limited to piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, pyrrolyl, 4-piperidinyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, pyridinyl, pyrazinyl, oxazolidinyl, oxazolinyl, oxazolyl, isoxazolyl, morpholinyl, thiazolidinyl, thiazolinyl, thiazolyl, furyl, pyranal, tetrahydrofuryl, tetrahydropyranyl, thienyl, tetrazolyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl, as well as triazolyl, thiadiazolyl, oxadiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyridazinyl, pyrimidinyl and triazinyl which


are available by routine chemical synthesis and are stable. The 5-6 membered heterocyclic group may be attached at any heteroatom or carbon atom that results in the creation of a stable structure. The 5-6 membered heterocyclic group may be optionally unsubstituted or substituted by one or more of the substituents independently selected from the group halo, cyano,


- 5 C₁-C₆ alkyl (which specifically includes C₁-C₆ haloalkyl, -C₀-C₆ alkyl-OH, -C₀-C₆ alkyl-SH and -C₀-C₆ alkyl-NR'R''), C₃-C₆ alkenyl, oxo, -OC₁-C₆alkyl, -OC₁-C₆ alkenyl, -C₀-C₆ alkyl-COR', -C₀-C₆ alkyl-CO₂R', -C₀-C₆ alkyl-CONR'R'', -OC₀-C₆ alkyl-CO₂H, -OC₂-C₆ alkyl-NR'R'', -C₀-C₆ alkyl-C(=NR'')NR'R'' and -C₀-C₆ alkyl-SO₂NR'R'', wherein each R' and R'' are independently selected from H or unsubstituted C₁-C₆ alkyl.

- 10 In the compounds of formulas (III) and (IV), the terms "halogen" and "halo" represent chloro, fluoro, bromo or iodo substituents; "alkoxy" is intended to mean the radical -OR_a, where R_a is an alkyl group, wherein alkyl is as defined above, provided that -O-C₁ alkyl may be optionally substituted by one or more of the substituents independently selected from the group halo and -CO₂H. (exemplary alkoxy groups include methoxy, ethoxy, propoxy, and the like);
- 15 "phenoxy" is intended to mean the radical -OR_{ar}, where R_{ar} is a phenyl group; "acetoxy" is intended to mean the radical -O-C(=O)-methyl; "benzoyloxy" is intended to mean the radical -O-C(=O)-phenyl; and "oxo" is intended to mean the keto diradical =O, such as present on a pyrrolidin-2-one ring.


A method for the preparation of compounds of formula (III), comprises the steps of:


- 20 (a) reacting an alcohol having the formula: HY'-(CR⁴R⁵)_n-L, where Y' is -O-, -S-, -NH or protected -NH and L is a leaving group, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving

group (e.g., an alcohol), with an alcohol having the formula: , where X is a protected carboxylic acid moiety, to form a compound having the



- (b) reacting the compound formed in step (a) with a secondary amine having the






(c) converting the protected carboxylic acid moiety into a desired amide moiety;

and


(d) optionally oxidizing the compound, formed in step (b) to the N-oxide thereof.

5 Another method for the preparation of compounds of formula (III), comprises the steps of:


(a) reacting an acetylene having the formula: $\text{R}'\text{O}-(\text{CR}^4\text{R}^5)_{n-1}-\text{C}\equiv\text{C}-\text{H}$, where R' is a hydroxyl protecting group, with a halogen-containing aromatic compound having the formula




10 , where X is a protected carboxylic acid moiety and Halo is bromo or iodo, in the presence of a catalyst to form a compound having the formula:




(b) reducing the compound formed in step (a) and converting the protected hydroxyl group into a leaving group, L, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group
15 (e.g., an alcohol), to form a compound having the formula:



(c) reacting the compound formed in step (b) with an amine having the formula:



to form a compound having the formula:



(d) converting the protected carboxylic acid moiety into a desired amide moiety;

and

(e) optionally oxidizing the compound formed in step (b) to the N-oxide thereof.

Another method for the preparation of compounds of formula (III), comprises the steps of:


(a) reacting an alcohol having the formula: $\text{L}' - (\text{CR}^4\text{R}^5)_n - \text{L}$, where L' and L are leaving groups, which may be the same or different, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving

group (e.g., an alcohol), with a compound having the formula: $\text{X} - (\text{CR}^1\text{R}^2)_p - \text{C}_6\text{H}_3(\text{R}^3)_k - \text{Y}' - \text{H}$, where Y' is $-\text{O}-$, $-\text{S}-$, or $-\text{NH}-$ and X is defined as above or a protected form thereof, to form a

compound having the formula: $\text{X} - (\text{CR}^1\text{R}^2)_p - \text{C}_6\text{H}_3(\text{R}^3)_k - \text{Y}' - (\text{CR}^4\text{R}^5)_n - \text{H}$;

(b) reacting the compound formed in step (a) with a secondary amine having the

formula $-(\text{CR}^8\text{R}^9)_q - \text{H}$ to form a compound having the formula:




(c) removing any protecting groups; and


(d) optionally oxidizing the compound formed in step (b) or (c) to the N-oxide thereof.

Another method for the preparation of compounds of formula (III), comprises the steps of:

- 5 (a) reacting a compound having the formula:




, where Y' is -O-, -S-, or -NH- and R' is a suitable protecting group for -OH, -SH, or -NH₂, with a hydrazide or azide to form a heterocyclic-containing compound having the formula:




- 10 (b) optionally protecting the NH moiety of the heterocyclic group with a protecting group, and removing the R' protecting group;

- (c) reacting the compound formed in step (b) with a compound having the formula: L'-(CR⁴R⁵)_n-L, , where L' and L are leaving groups, which may be the same or different, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol), to form a compound having the formula:




, where P is an optional protecting group or H;

- (d) reacting the compound formed in step (c) with an amine having the formula:



20


to form a compound having the structure:




(e) removing any protecting groups.

Another method for the preparation of compounds of formula (III), comprises the steps

5 (a) reacting an acetylene having the formula: $R'O-(CR^4R^5)_{n-1}-C\equiv C-H$, where R' is a hydroxyl protecting group, with a halogen-containing aromatic compound having the formula




, where Halo is bromo or iodo, in the presence of a catalyst




to form a compound having the formula:

(b) reducing the compound formed in step (a) and converting the protected hydroxyl group into a leaving group, L, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol) to form a compound having the formula:



- (c) reacting the compound formed in step (b) with an amine having the formula:





- (d) removing any protecting groups; and


- 5 (e) optionally oxidizing the compound formed in step (c) or (d) to the N-oxide thereof.

Another method for the preparation of compounds of formula (III), comprises the steps of:


- 10 (a) reacting an alcohol having the formula: $HO-(CR^4R^5)_n-L$, where L is a leaving group, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol) with a phenol having



- 15 (b) reacting an amine having the formula $H_2N-\begin{matrix} W^1 \\ | \\ W^2 \\ | \\ R^6 \\ | \\ R^7 \end{matrix}$ with and an aldehyde having the formula $Q-CHO$ or a ketone to form a secondary amine having the formula:



- (c) reacting the ether formed in step (a) with the secondary amine formed in step (b) to form a compound of this invention having the formula:




(d) when R^{10} is other than H, optionally converting the compound. formed in step (c) to the compound of this invention, wherein R^{10} is H.

Another method for the preparation of compounds of formula (III), comprises the steps of:


(a) reacting an alcohol having the formula: $HO-(CR^4R^5)_n-L$, where L is a leaving group, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol), with an amine having

the formula:




to form a tertiary amine having the formula:

(b) reacting the tertiary amine formed in step (a) with a phenol having the formula:




to form a compound of this invention having the formula:




(c) when R^{10} is other than H, optionally converting the compound. formed in step (b) to the compound of this invention, wherein R^{10} is H.

Another method for the preparation of compounds of formula (III), comprises the steps of:


(a) reacting an alcohol having the formula: $\text{HO}-(\text{CR}^4\text{R}^5)_n\text{-L}$, where L is a leaving group, such as a halogen (iodide, bromide or chloride) or sulfonate (tosylate, mesylate, triflate, etc.), with a phenol having the formula:




5 to form an ether-alcohol having the formula:



(b) converting alcohol moiety of the ether-alcohol formed in step (a) into L', where L' is a leaving group such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol) and treating the resulting compound with an amine having the formula:




to form a compound of this invention having the formula:




(c) when R^{10} is other than H, optionally converting the compound. formed in step (b) to the compound of this invention, wherein R^{10} is H.

The method for the preparation of compounds of formula (IV), comprises the steps of:


(a) coupling an acetylene having the formula: with a phenol having the formula:



20 , where Halo is a halogen selected from iodo or bromo, in the presence of a metal catalyst to form an aryl-alcohol having the formula:




- (b) converting alcohol moiety of the aryl-alcohol formed in step (a) into L', where L' is a leaving group such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol), and
- 5 treating the resulting compound with an amine having the formula:




to form the compound of formula (IV);


- (c) optionally converting the compound of formula (IV) from step (b) into another compound of formula (IV); and
- 10 (d) optionally oxidizing the compound formed in step (c) to the N-oxide thereof. Alternatively, the compounds of formula (IV) may be prepared by
- (a) coupling an acetylene having the formula: with a phenol having the formula:




, where Halo is a halogen selected from iodo or bromo, in the presence of a metal catalyst to form an aryl-alcohol having the formula:



- (b) converting alcohol moiety of the aryl-alcohol formed in step (a) into L', where L' is a leaving group such as a halogen (iodide, bromide or chloride) or a sulfonate (tosylate, mesylate, triflate, etc.) and treating the resulting compound with sodium azide, followed by
- 20 hydrogenation in the presence of a palladium catalyst to form a primary amine having the formula:




- (c) treating the primary amine with a first aldehyde in the presence of a reducing agent, to form a secondary amine and treating the secondary amine with a second aldehyde in
- 25 the presence of a reducing agent to form the compound of formula (IV);



(d) optionally converting the compound of formula (IV) from step (b) into another compound of formula (IV); and

(e) optionally oxidizing the compound, formed in step (b) or (c) to the N-oxide thereof.

International Patent Applications WO 01/41704 (Merck & Co., Inc.) discloses compound of formula (V)



(V)

as being an agonist of LXR and its use in pharmaceutical formulations to prevent and treat atherosclerotic disease.

Other LXR agonists may be identified by assays such as those described in the above referenced patent applications, for example, the assays described in Examples 1 and 2 of PCT/US01/27622. Biotinylated LXR β protein was incubated for 20-25 minutes at a concentration of 25nM in assay buffer (50mM KCl, 50mM Tris-pH8, 0.1mg/ml FAF-BSA,

10mM DTT) with equimolar amounts of streptavidin-AlloPhycoCyanin (APC, Molecular Probes). At the same time, the biotinylated peptide comprising amino acids 675-699 of SRC-1 (CPSSHSSLTERHKILHRLQEGSPS-CONH₂) (SEQ ID NO: 5) at a concentration of 25nM was incubated in assay buffer with a ½ molar amount of streptavidin-labelled Europium (Wallac) for 20-25 minutes. After the initial incubations are completed, a 10 molar excess (250nM) of cold biotin was added to each of the solutions to block the unattached streptavidin reagents. After 20 min at room temp, the solutions were mixed yielding a concentration of 12.5nM for the dye-labelled LXRβ protein and SRC-1 peptide. 80μL of the protein/peptide mixture was added to each well of an assay plate containing 20μL of test compound. The final volume in each well was 0.1mL, and the concentration in the well for the dye-labelled protein and peptide was 10nM. The final test compound concentrations were between 56pM and 10μM. The plates were incubated at room temp in the dark for 4-12 hours and then counted on a Wallac Victor fluorescent plate reader. In this assay 1μM 24(S),25-epoxycholesterol gave a reading of 20000 fluorescence units over a background reading of 10000 fluorescence units. The assay for LXRα was run according to the procedures described above using his-tagged LXRα ligand binding domain (amino acids 183-447 of Genbank accession number U22662, with the 14th amino acid corrected to A from R).

Suitable pharmaceutically acceptable salts include salts of salts derived from appropriate acids, such as acid addition salts, or bases.

Suitable pharmaceutically acceptable salts include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-b-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.

Suitable acid addition salts include pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methane-sulphonate, α-keto glutarate and α-glycerophosphate.

The LXR agonists referred to herein are conveniently prepared according to the methods disclosed in the above mentioned patent publications in which they are disclosed.

The salts and/or solvates of the LXR agonists may be prepared and isolated according to conventional procedures for example those disclosed in the, above mentioned, patent publications.

5 In the above mentioned method the LXR agonist, may be administered per se or, preferably, as a pharmaceutical composition/formulation also comprising a pharmaceutically acceptable carrier.

In the treatment of the invention, the LXR agonist mentioned herein is formulated and administered in accordance with the methods disclosed in the above mentioned patent applications and patents.

10 As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' also embraces a veterinarily acceptable salt.

Preferred "mammal" of the present invention is a human being.

15 The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.

Usually the pharmaceutical compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection, enema, colonoscopic infusion, infusion into the small bowel via an endoscope or intubation, and percutaneous absorption are also envisaged.

20 Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used.

25 In accordance with conventional pharmaceutical practice, the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant.

Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, sodium lauryl sulphate or sucrose.

30 The solid oral compositions may be prepared by conventional methods of blending, filling or tableting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

35 Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin,

hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

Compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.

The compositions are formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) and Harry's Cosmeticology (Leonard Hill Books).

Typically, a therapeutically effective amount of LXR agonist of the present invention for preventing or treating eosinophilia or IL-13 overproduction, or diseases arising from eosinophilia or IL-13 production, such as asthma or allergy (for example allergic rhinitis), will depend upon a number of factors including, for example, the age and weight of the mammal, the precise condition requiring treatment, the severity of the condition, the nature of the formulation, and the route of administration. Ultimately, the therapeutically effective amount will be at the discretion of the attendant physician or veterinarian.


Typically, the LXR agonist agent will be given in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 1 to 30 mg/kg body weight per day. Acceptable daily dosages of the LXR agonist for preventing/treating eosinophilia or IL-13 overproduction, or diseases arising from eosinophilia or IL-13

production, such as asthma or allergy (for example allergic rhinitis), may be from about 0.1 to about 1000 mg/day, and preferably from about 0.2 to about 100 mg/day.

The following Examples are intended for illustration only and are not intended to limit the scope of the invention in any way; the present invention being defined by the appended claims.

EXAMPLES

10 **Example 1: 2-(3-{3-[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-phenyl)acetic acid (Compound B)**



Argogel-MB-OH (6.0g, 2.40mmol, Argonaut Technologies) was treated with a solution of (3-{*tert*-butyl(dimethyl)silyl]oxy}phenyl)acetic acid (5.40g, 19.2 mmol, Eur. Pat. Appl. (1987)
 15 Application: EP 87-303742 19870428) in 50 mL of anhydrous dichloromethane followed by dicyclohexylcarbodiimide (4.16g, 19.2 mmol) and 4-dimethylaminopyridine (2.50 g, 19.2 mmol). After rotating at room temperature for 15 hours, the resin was filtered, washed sequentially with dichloromethane (2 x 25 mL), dimethylformamide (2 x 25mL),
 20 dichloromethane (3 x 25 mL), methanol (3 x 25 mL), dichloromethane (3 x 25 mL) and diethyl ether (2 x 25 mL). After drying under house vacuum overnight at 40°C, the resin was treated with 1.0 M tetrabutylammonium fluoride (24 mL, 23.4 mmol) in tetrahydrofuran, and the mixture was rotated for 4 hours. The resin was filtered, washed sequentially with
 25 dichloromethane (2 x 25 mL), dimethylformamide (2 x 25 mL), dichloromethane (3 x 25 mL), methanol (3 x 25 mL), and dichloromethane (3 x 25 mL) to give the deprotected phenol. The dry resin was treated with 90 mL of anhydrous toluene followed by triphenylphosphine (15.8 g, 60.0 mmol) and 3-bromo-1-propanol (8.4 g, 60.0 mmol). Upon cooling to 0°C, diisopropyl azodicarboxylate (12.1 g, 60.0 mmol) in 20 mL of anhydrous toluene was added in a dropwise fashion. The reaction was allowed to warm to room temperature and stirred for 15 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 50 mL), dimethylformamide
 30 (2 x 50 mL), dichloromethane (3 x 50 mL), methanol (2 x 50 mL) and dichloromethane (3 x 50 mL), and dried under house vacuum. The bromide functionalized resin was treated with a solution of diphenethylamine (25.0 g, 127 mmol) in 60 mL of anhydrous dimethylsulfoxide,

and the reaction was rotated for 15 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 50 mL), dimethylformamide (2 x 50 mL), dichloromethane (3 x 50 mL), methanol (3 x 50 mL) and dichloromethane (3 x 50 mL), and dried under house vacuum at 40°C. The secondary amine resin (5.75 g, 2.0 mmol) was treated with a solution of 2-chloro-3-trifluoromethylbenzaldehyde (8.32 g, 40.0 mmol) in 80 mL of 8% acetic acid in dimethylformamide. Solid sodium triacetoxyborohydride (8.5 g, 40.0 mmol) was added, and the reaction was rotated for 15 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 50 mL), dimethylformamide (2 x 50 mL), dichloromethane (3 x 50 mL), methanol (3 x 50 mL) and dichloromethane (3 x 50 mL), and dried under house vacuum overnight at 50°C. The resin-bound product was treated with 30 mL of trifluoroacetic acid/dichloromethane (15/85) for 15 minutes, and the filtrate was collected. The cleavage procedure was repeated again, and the combined filtrates were concentrated under reduced pressure. The crude product was purified by preparative thin layer chromatography (silica gel, 1 mm plates, Merck 20 x 20 cm silica gel 60 F₂₅₄) eluting with methanol:dichloromethane (3:97) to give 7.0 mg of the title compound (5% yield based on theoretical loading of secondary amine resin) of a viscous oil: ¹H NMR (CDCl₃, 400MHz) δ 7.42 (d, 1 H, J = 7.6), 7.23-7.10 (m, 12 H), 6.85 (t, 2 H, J = 8.1), 6.63 (s, 1 H), 6.61 (s, 1 H), 4.11 (t, 1 H, J = 7.8), 3.75 (s, 2 H), 3.63 (t, 2 H, J = 6.0), 3.59 (s, 2 H), 2.12 (d, 2 H, J = 7.8), 2.67 (t, 2 H, J = 6.6), 1.81 (tt, 2 H, J = 6.2); MS (ESP+) *m/e* 582 (MH⁺); TLC (EtOAc:hexanes/1:1) R_f = 0.58.

BIOLOGICAL SECTION

Sensitization and allergen challenge

Male Brown Norway rats, 6 weeks of age, were intraperitoneally injected with ovalbumin (OVA, 1 mg) along with Al(OH)₃ (100 mg) in 1ml of saline for three consecutive days. Three weeks after the third OVA-Al(OH)₃ injection, the animals were made to inhale aerosolized 3% OVA in saline delivered with an ultrasonic nebulizer for 20 min. Animals in the saline inhalation group were exposed to aerosolized saline.

Measurement of inflammatory cell number in the bronchoalveolar lavage fluid (BALF)

Bronchoalveolar lavage was performed with 10 ml (2 ml x 5) of PBS warmed at 37°C 24 hr after OVA or saline challenge. The number of total cells in BALF was counted with a microcell-counter. Cytospin slides were prepared and stained with Diff-Quik. Differential cell counting of at least 300 cells was performed according to the standard morphologic criteria under light microscopy.

Determination of IL-13 in the BALF

IL-13 concentration in the BALF was determined with ELISA kit (Biosource, USA).

Experimental design

Compound B (hereinafter used as monohydrochloride salt in this BIOLOGICAL SECTION) and Compound A (free base) were suspended in 0.5% methylcellulose solution. Compound B (10 and 30 mg/kg, b.i.d.), Compound A (100 mg/kg, q.d.) or vehicle was orally administered for three days until the day of antigen challenge.

The experimental groups were set up as follows:

- Saline challenge - vehicle
- 10 OVA challenge - vehicle
- OVA challenge – Compound B 10mg/kg
- OVA challenge – Compound B 30mg/kg
- OVA challenge – Compound A 100mg/kg

Results

15 Effects of Compound B on cell number and IL-13 concentration in BALF.

The effects of Compound B and Compound A on cell number and IL-13 concentration in BALF were shown in Tables A and B. Compound B (10 and 30 mg/kg, p.o., b.i.d) and Compound A (100 mg/kg, p.o., q.d.) significantly inhibited the increases in eosinophils and IL-13 concentration in BALF, and Compound B at a dose of 30 mg/kg and Compound A inhibited the increases in total cells in BALF 24 hr after the OVA challenge.

Table A. Effects of Compound B and Compound A on total cell and eosinophil number and IL-13 concentration in BALF.

| | Dose (mg/kg) | Route | n | Total cells in BALF | | Eosinophils in BALF | |
|------------------|-----------------|-------|---|-------------------------------------|--------------|-------------------------------------|--------------|
| | | | | (x10 ⁵ / recovered BALF) | | (x10 ⁵ / recovered BALF) | |
| | | | | Mean±SE | % inhibition | Mean±SE | % inhibition |
| Saline – vehicle | - | p.o. | 8 | 5.8±0.5 | - | 0.5±0.1 | - |
| OVA – vehicle | - | p.o. | 8 | 93.6±14.7 ^{**} | - | 18.3±2.3 ^{**} | - |
| Compound B | 10, bid | p.o. | 8 | 50.7±10.2 | 49 | 9.0±2.2 ⁺ | 52 |
| Compound B | 30, bid | p.o. | 8 | 39.6±9.2 ⁺ | 61 | 6.6±1.4 ⁺ | 66 |
| Compound A | 100,qd | p.o. | 9 | 28.4±4.1 ⁺ | 74 | 3.4±0.9 ⁺ | 84 |

**: $p < 0.01$ compared with the saline-vehicle group by Student's *t*-test. +: $p < 0.05$ compared with the OVA-vehicle group by Dunnett's test.

Table B. Effects of Compound B and Compound A on IL-13 concentration in BALF.

| | Dose (mg/kg) | Route | n | IL-13 concentration (pg/ml) | |
|------------------|-----------------|-------|---|-----------------------------|--------------|
| | | | | Mean \pm SE | % inhibition |
| Saline - vehicle | - | p.o. | 8 | 21.8 \pm 3.6 | - |
| OVA - vehicle | - | p.o. | 8 | 95.6 \pm 21.5 ** | - |
| Compound B | 10, bid | p.o. | 8 | 38.3 \pm 5.9 + | 78 |
| Compound B | 30, bid | p.o. | 8 | 35.9 \pm 7.2 + | 81 |
| Compound A | 100,qd | p.o. | 9 | 26.8 \pm 3.0 + | 93 |

**: $p < 0.01$ compared with the saline-vehicle group by Student's *t*-test. +: $p < 0.05$ compared with the OVA-vehicle group by Dunnett's test.

References

1. Peet DJ, Janowski BA, Mangelsdorf DJ. The LXRs: a new class of oxysterol receptors. *Curr Opin Genet Dev* 1998;8(5):571-5.
2. Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. *Mol Cell Biol* 1994;14(10):7025-35.
3. Teboul M, Enmark E, Li Q, Wikstrom AC, Pelto-Huikko M, Gustafsson JA. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. *Proc Natl Acad Sci U S A* 1995;92(6):2096-100.
4. Song C, Kokontis JM, Hiipakka RA, Liao S. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. *Proc Natl Acad Sci U S A* 1994;91(23):10809-13.
5. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR,

- a nuclear receptor that defines a distinct retinoid response pathway. *Genes Dev* 1995;9(9):1033-45.
6. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, et al.
5 Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. *Cell* 1998;93(5):693-704.
7. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. *J Clin Invest* 2000;105(4):513-20.
10 22
8. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al.
Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. *Genes Dev* 2000;14(22):2819-30.
15
9. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. *Genes Dev* 2000;14(22):2831-8.
10. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, et al.
20 LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. *Proc Natl Acad Sci U S A* 2001;98(2):507-12.
11. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. *J Biol Chem* 2000;275(36):28240-5.
25
12. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. *Science* 2000;289(5484):1524-9.
13. Venkateswaran A, Repa JJ, Lobaccaro JM, Bronson A, Mangelsdorf DJ, Edwards PA. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. *J Biol Chem* 2000;275(19):14700-7.
30
- 14 Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. *Proc Natl Acad Sci U S A* 2000;97(22):12097-102.
35

15. Schwartz K, Lawn RM, Wade DP. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. *Biochem Biophys Res Commun* 2000;274(3):794-802.

5

The above description fully discloses how to make and use the present invention. However, this invention is not limited to the particular embodiments described hereinabove, but includes all modification thereof within the scope of the appended claims and their equivalents. Those skilled in the art will recognize through routine experimentation that various changes and
 10 modifications can be made without departing from the scope of this invention. The various references to journals, patents and other patent applications that are cited herein are incorporated by reference herein as though fully set forth.

Table 1

15

ATGTCCTTGTGGCTGGGGGCCCCCTGTGCCTGACATTCCTCCTGACTCTGCGGTGGA
 GCTGTGGAAGCCAGGCGCACAGGATGCAAGCAGCCAGGCCAGGGAGGCAGCAG
 CTGCATCCTCAGAGAGGAAGCCAGGATGCCCCACTCTGCTGGGGGTACTGCAGGG
 GTGGGGCTGGAGGCTGCAGAGCCCACAGCCCTGCTCACCAGGGCAGAGCCCCCTT
 20 CAGAACCCACAGAGATCCGTCCACAAAAGCGGAAAAGGGGCCAGCCCCAAAAT
 GCTGGGGAACGAGCTATGCAGCGTGTGTGGGGACAAGGCCTCGGGCTTCCACTAC
 AATGTTCTGAGCTGCGAGGGCTGCAAGGGATTCTTCCGCCGCAGCGTCATCAAGGG
 AGCGCACTACATCTGCCACAGTGGCGGCCACTGCCCCATGGACACCTACATGCGTC
 GCAAGTGCCAGGAGTGTCTGGCTTCGCAAATGCCGTCAGGCTGGCATGCGGGAGGA
 25 GTGTGTCCTGTCAGAAGAACAGATCCGCCTGAAGAACTGAAGCGGCAAGAGGAG
 GAACAGGCTCATGCCACATCCTTGCCCCCAGGCGTTCTCACCCCCCAAATCCT
 GCCCCAGCTCAGCCCGGAACAACCTGGGCATGATCGAGAAGCTCGTCGCTGCCCAG
 CAACAGTGTAACCGGCGCTCCTTTTCTGACCGGCTTCGAGTCACGCCTTGGCCCAT
 GGCACCAGATCCCCATAGCCGGGAGGCCCGTCAGCAGCGCTTTGCCCACTTCACTG
 30 AGCTGGCCATCGTCTCTGTGCAGGAGATAGTTGACTTTGCTAAACAGCTACCCGGC
 TTCCTGCAGCTCAGCCGGGAGGACCAGATTGCCCTGCTGAAGACCTCTGCGATCGA
 GGTGATGCTTCTGGAGACATCTCGGAGGTACAACCCTGGGAGTGAGAGTATCACCT
 TCCTCAAGGATTTTCAAGTTATAACCGGGAAGACTTTGCCAAAGCAGGGCTGCAAGTG
 GAATTCATCAACCCCATCTTCGAGTTCTCCAGGGCCATGAATGAGCTGCAACTCAA
 35 TGATGCCGAGTTTGCCTTGCTCATTGCTATCAGCATCTTCTCTGCAGACCGGCCCAA
 CGTGCAGGACCAGCTCCAGGTGGAGAGGCTGCAGCACACATATGTGGAAGCCCTG
 CATGCCTACGTCTCCATCCACCATCCCCATGACCGACTGATGTTCCACGGATGCT

AATGAAACTGGTGAGCCTCCGGACCCTGAGCAGCGTCCACTCAGAGCAAGTGTTTG
 CACTGCGTCTGCAGGACAAAAAGCTCCCACCGCTGCTCTCTGAGATCTGGGATGTG
 CACGAATGA

5

Table 2

MSLWLGA PVPDIPDS AVELWKPGAQDASSQAQGGSSCILREEARMPHSAGGTAGVG
 LEAAEPTALLTRAEPPEPTAIRPQKRKKGPAPKMLGNELCSVCGDKASGFHYNVLSCE
 GCKGFFRRSVIKGAHYICHSGGHCPMDTYMRRKCQECRLRKCRQAGMREECVLSEEQ
 10 IRLKKLKRQEEEAHATSLPPRRSSPPQILPQLSPEQLGMIEKLVAQQQCNRRSFSDDL
 RVTPWPMAPDPHSREARQQRFAHFTELAIVSVQEIVDFAKQLPGFLQLSREDQIALKLT
 SAIEVMLLETSSRRYNPGSESITFLKDFSYNREDFAKAGLQVEFINPIFEFSRAMNELQLN
 DAEFALLIAISIFSADRPNVQDQLQVERLQHTYVEALHAYVSIHHPHDLRMFPRMLMK
 LVSLRTLSSV HSEQVFALRLQDKKLPLLSEIWDVHE

15

Table 3

ATGTCCTCTCCTACCACGAGTTCCTGGATACCCCCCTGCCTGGAAATGGCCCCCCT
 CAGCCTGGCGCCCCCTTCTTCTTCACCACTGTAAAGGAGGAGGGTCCGGAGCCGTG
 GCCCGGGGGTCCGGACCCTGATGTCCAGGCACTGATGAGGCCAGCTCAGCCTGC
 20 AGCACAGACTGGGTCATCCAGATCCCGAAGAGGAACCAGAGCGCAAGCGAAAG
 AAGGGCCCAGCCCCGAAGATGCTGGGCCACGAGCTTTGCCGTGTCTGTGGGGACA
 AGGCCTCCGGCTTCCACTACAACGTGCTCAGCTGCGAAGGCTGCAAGGGCTTCTTC
 CGGCGCAGTGTGGTCCGTGGTGGGGCCAGGCGCTATGCCTGCCGGGGTGGCGGAA
 CCTGCCAGATGGACGCTTTCATGCGGCGCAAGTGCCAGCAGTGCCGGCTGCGCAA
 25 GTGCAAGGAGGCAGGGATGAGGGAGCAGTGCGTCCTTTCTGAAGAACAGATCCGG
 AAGAAGAAGATTCGGAAACAGCAGCAGGAGTCACAGTCACAGTCGCAGTCACCTG
 TGGGGCCGCAGGGCAGCAGCAGCTCAGCCTCTGGGCCTGGGGCTTCCCCTGGTGG
 ATCTGAGGCAGGCAGCCAGGGCTCCGGGGAAGGCGAGGGTGTCCAGCTAACAGCG
 GCTCAAGAACTAATGATCCAGCAGTTGGTGGCGGCCCAACTGCAGTGCAACAAAC
 30 GCTCCTTCTCCGACCAGCCCAAAGTCACGCCCTGGCCCCCTGGGCGCAGACCCCCAG
 TCCCGAGATGCCCGCCAGCAACGCTTTGCCCACTTCACGGAGCTGGCCATCATCTC
 AGTCCAGGAGATCGTGGACTTCGCTAAGCAAGTGCCCTGGTTTCCTGCAGCTGGGCC
 GGGAGGACCAGATCGCCCTCCTGAAGGCATCCACTATCGAGATCATGCTGCTAGA
 GACAGCCAGGCGCTACAACCACGAGACAGAGTGTATCACCTTCTTGAAGGACTTC
 35 ACCTACAGCAAGGACGACTTCCACCGTGCAAGCCTGCAGGTGGAGTTCATCAACCC
 CATCTTCGAGTTCTCGCGGGCCATGCGGCGGCTGGGCCTGGACGACGCTGAGTACG
 CCCTGCTCATCGCCATCAACATCTTCTCGGCCGACCGGCCCAACGTGCAGGAGCCG

GGCCGCGTGGAGGCGTTGCAGCAGCCCTACGTGGAGGCGCTGCTGTCCTACACGC
 GCATCAAGAGGCCGCGAGGACCAGCTGCGCTTCCCGCGCATGCTCATGAAGCTGGT
 GAGCCTGCGCACGCTGAGCTCTGTGCACTCGGAGCAGGTCTTCGCCTTGCGGCTCC
 AGGACAAGAAGCTGCCGCCTCTGCTGTGCGGAGATCTGGGACGTCCACGAGTGA


5

Table 4

MSSPTTSSLDTPLPGNGPPQPGAPSSSPTVKEEGPEPWPGGPDVPGTDEASSACSTD
 10 WVIPDPEEERKRKKGPAPKMLGHELCRVCGDKASGFHYNVLSCEGCKGFFRRSVV
 RGGARRYACRGGGTCQMDAFMRRKCQCRLRKCKEAGMREQCVLSEEQIRKKKIRK
 QQESQSQSQSPVGPQGSSSSASGPGASPGGSEAGSQSGEGEGVQLTAAQELMIQQL
 VAAQLQCNKRSFSDQPKVTPWPLGADPQSRDARQQRFAHFTELAISVQEIVDFAKQV
 PGFLQLGREDQIALLKASTIEIMLLETARRYNHETECITFLKDFTYSKDDFHRAGLQVEF
 15 INPIFEFSRAMRRLGLDDAEYALLIAINIFSADRPNVQEPGRVEALQQPYVEALLSYTRI
 KRPQDQLRFPRMLMKLVSLRTLSSVHSEQVFALRLQDKKLPLLSEIWDVHE

What is claimed is:

1. A method of treating or preventing in a mammal eosinophilia or IL-13 overproduction, or diseases caused by eosinophilia or overproduction of IL-13; comprising, administering a therapeutically effective amount of LXR agonist, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
2. The method of claim 1 in which the disease is asthma or allergy.
3. The method of claim 2 in which the allergy is allergic rhinitis.
4. A pharmaceutical composition for treating or preventing in a mammal eosinophilia or IL-13 overproduction, or diseases caused by eosinophilia or overproduction of IL-13; comprising, administering a therapeutically effective amount of LXR agonist, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
5. The pharmaceutical composition of claim 4 in which the disease is asthma or allergy.
6. The pharmaceutical composition of claim 5 in which the allergy is allergic rhinitis.
7. The method according to claim 1, 2, or 3 wherein the LXR agonist is a compound of formula (II):



wherein:

- X is OH or NH₂;
- p is 0-6;
- each R¹ and R² are the same or different and are each independently selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₁₋₈thioalkyl;
- Z is CH or N;
- when Z is CH, k is 0-4;
- when Z is N, k is 0-3;

each R^3 is the same or different and is independently selected from the group consisting of halo,
 $-OH$, $C_{1-8}alkyl$, $C_{2-8}alkenyl$, $C_{1-8}alkoxy$, $C_{2-8}alkenyloxy$,
 $-S(O)_aR^6$, $-NR^7R^8$, $-COR^6$, $COOR^6$, $R^{10}COOR^6$, $OR^{10}COOR^6$, $CONR^7R^8$, $-OC(O)R^9$,
 $-R^{10}NR^7R^8$, $-OR^{10}NR^7R^8$, 5-6 membered heterocycle, nitro, and cyano;

5 a is 0, 1 or 2;

R^6 is selected from the group consisting of H, $C_{1-8}alkyl$, $C_{1-8}alkoxy$ and
 $C_{2-8}alkenyl$;

each R^7 and R^8 are the same or different and are each independently selected from the
group consisting of H, $C_{1-8}alkyl$, $C_{2-8}alkenyl$,

10 $C_{3-8}alkynyl$;

R^9 is selected from the group consisting of H, $C_{1-8}alkyl$ and $-NR^7R^8$;

R^{10} is $C_{1-8}alkyl$;

n is 2-8;

q is 0 or 1;


15 R^4 is selected from the group consisting of H, $C_{1-8}alkyl$, $C_{1-8}alkenyl$, and alkenyloxy;

Ring A is selected from the group consisting of $C_{3-8}cycloalkyl$, aryl, 4-8 membered heterocycle,
and 5-6 membered heteroaryl;


each ring B is the same or different and is independently selected from the group consisting of
 $C_{3-8}cycloalkyl$ and aryl.

20

8. The method according to claim 7, in which the LXR agonist is the compound of the
formula




9. The pharmaceutical composition of claim 4, 5 or 6, in which the LXR agonist is a compound of formula (II):



wherein:


- 5 X is OH or NH₂;
p is 0-6;
each R¹ and R² are the same or different and are each independently selected from the group
consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and C₁₋₈thioalkyl;
Z is CH or N;
10 when Z is CH, k is 0-4;
when Z is N, k is 0-3;
each R³ is the same or different and is independently selected from the group consisting of halo,
-OH, C₁₋₈alkyl, C₂₋₈alkenyl, C₁₋₈alkoxy, C₂₋₈alkenyloxy,
-S(O)_aR⁶, -NR⁷R⁸, -COR⁶, COOR⁶, R¹⁰COOR⁶, OR¹⁰COOR⁶, CONR⁷R⁸, -OC(O)R⁹,
15 -R¹⁰NR⁷R⁸, -OR¹⁰NR⁷R⁸, 5-6 membered heterocycle, nitro, and cyano;
a is 0, 1 or 2;
R⁶ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkoxy and
C₂₋₈alkenyl;
each R⁷ and R⁸ are the same or different and are each independently selected from the
20 group consisting of H, C₁₋₈alkyl, C₂₋₈alkenyl,
C₃₋₈alkynyl;
R⁹ is selected from the group consisting of H, C₁₋₈alkyl and -NR⁷R⁸;
R¹⁰ is C₁₋₈alkyl;
n is 2-8;
25 q is 0 or 1;
R⁴ is selected from the group consisting of H, C₁₋₈alkyl, C₁₋₈alkenyl, and alkenyloxy;
Ring A is selected from the group consisting of C₃₋₈cycloalkyl, aryl, 4-8 membered heterocycle,
and 5-6 membered heteroaryl;
each ring B is the same or different and is independently selected from the group consisting of
30 C₃₋₈cycloalkyl and aryl.

10. The pharmaceutical composition of claim 9 in which the LXR agonist is the compound of the formula



5

11. The method according to claim 1, 2 or 3 wherein the LXR agonist is a compound of formula (I):



(I)

wherein:

Ar represents an aryl group; R¹ is –

- 15 OH, -O-(C₁-C₇)alkyl, -OC(O)-(C₁-C₇)alkyl, -O-(C₁-C₇)heteroalkyl, -OC(O)-(C₁-C₇)heteroalkyl, -CO₂H, -NH₂, -NH(C₁-C₇)alkyl, -N((C₁-C₇)alkyl)₂ or – NH-S(O)₂-(C₁-C₅)alkyl;

R² is (C₁-C₇)alkyl, (C₁-C₇)heteroalkyl, aryl and aryl(C₁-C₇)alkyl;

X¹, X², X³, X⁴, X⁵ and X⁶ are each independently H, (C₁-C₅)alkyl, (C₁-C₅)heteroalkyl, F or Cl, with the proviso that no more than three of X¹ through X⁶ are H, (C₁-C₅)alkyl or (C₁-C₅)heteroalkyl; and

Y is -N(R¹²)S(O)_m-, -N(R¹²)S(O)_mN(R¹³)-, -N(R¹²)C(O)-, –


N(R¹²)C(O)N(R¹³)-, -N(R¹²)C(S)- or -N(R¹²)C(O)O-, wherein R¹² and R¹³ are each independently hydrogen, (C₁-C₇)aryl, (C₁-C₇)heteroalkyl, aryl and

aryl(C₁-C₇)alkyl, and optionally when Y is –

N(R¹²)S(O)_m- or -N(R¹²)S(O)_mN(R¹³)-, R¹² forms a five, six or seven-membered ring fused to Ar or to R² through covalent attachment to Ar or R², respectively. In the above Y groups, the subscript m is an integer of from 1 to 2.


5

12. The method according to claim 11 in which the LXR agonist is the compound of the formula



10

13. A pharmaceutical composition of claim 4, 5, or 6 in which the LXR agonist is a compound of formula (I)



(I)

15

wherein:

Ar represents an aryl group; R¹ is –

OH, -O-(C₁-C₇)alkyl, -OC(O)-(C₁-C₇)alkyl, -O-(C₁-C₇)heteroalkyl, -OC(O)-(C₁-C₇)heteroalkyl, -CO₂H, -NH₂, -NH(C₁-C₇)alkyl, -N((C₁-C₇)alkyl)₂ or –

20

NH-S(O)₂-(C₁-C₅)alkyl;

R² is (C₁-C₇)alkyl, (C₁-C₇)heteroalkyl, aryl and aryl(C₁-C₇)alkyl;

X¹, X², X³, X⁴, X⁵ and X⁶ are each independently H, (C₁-C₅)alkyl, (C₁-C₅)heteroalkyl, F or Cl, with the proviso that no more than three of X¹ through X⁶ are H, (C₁-C₅)alkyl or (C₁-C₅)heteroalkyl; and

25


Y is -N(R¹²)S(O)_m-, -N(R¹²)S(O)_mN(R¹³)-, -N(R¹²)C(O)-, –

N(R¹²)C(O)N(R¹³)-, -N(R¹²)C(S)- or -N(R¹²)C(O)O-, wherein R¹² and R¹³ are each independently hydrogen, (C₁-C₇)aryl, (C₁-C₇)heteroalkyl, aryl and aryl(C₁-C₇)alkyl, and optionally when Y is –

N(R¹²)S(O)_m- or -N(R¹²)S(O)_mN(R¹³)-, R¹² forms a five, six or seven-membered

ring fused to Ar or to R² through covalent attachment to Ar or R², respectively. In the above Y groups, the subscript m is an integer of from 1 to 2.

- 5 14. The pharmaceutical composition of claim 13 in which the LXR agonist is the compound of the formula



SEQUENCE LISTING

<110> KIKKAWA, Hideo
KINOSHITA, Mine
KURUSU, Osamu

<120> METHODS OF TREATMENT WITH LXR AGONISTS

<130> TB00010

<140> Not Yet Assigned

<141> 2004-12-03

<150> 60/526,770

<151> 2003-12-03

<160> 5

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1344

<212> DNA

<213> Homo sapien

<400> 1

```

atgtccttgt ggctgggggc ccctgtgcct gacattcctc ctgactctgc ggtggagctg 60
tggaagccag ggcacagga tgcaagcagc caggcccagg gaggcagcag ctgcatcctc 120
agagaggaag ccaggatgcc ccaactctgt ggggggtactg caggggtggg gctggaggct 180
gcagagccca cagccctgct caccagggca gagccccctt cagaaccac agagatccgt 240
ccacaaaagc ggaaaaaggg gccagccccc aaaatgctgg ggaacgagct atgcagcgtg 300
tgtggggaca aggcctcggg cttccactac aatgttctga gctgcgaggg ctgcaaggga 360
ttcttcgcgc gcagcgtcat caagggagcg cactacatct gccacagtgg cggccactgc 420
cccatggaca cctacatgcg tcgcaagtgc caggagtgtc ggcttcgcaa atgccgtcag 480
gctggcatgc gggaggagtg tgtcctgtca gaagaacaga tccgcctgaa gaaactgaag 540
cggcaagagg aggaacaggc tcatgccaca tccttgcccc ccaggcgttc ctcaccccc 600
caaatcctgc ccagctcag ccggaacaa ctgggcatga tcgagaagct cgtcgtgcc 660
cagcaacagt gtaaccggcg ctccctttct gaccggcttc gagtcacgcc ttggcccatg 720
gcaccagatc cccatagccg ggaggcccg cagcagcgtt ttgcccactt cactgagctg 780
gccatcgtct ctgtgcagga gatagttgac tttgctaaac agctacccgg cttcctgcag 840
ctcagccggg aggaccagat tgccctgctg aagacctctg cgatcgaggt gatgcttctg 900
gagacatctc ggaggtacaa ccctgggagt gagagtatca ccttcctcaa ggatttcagt 960
tataaccggg aagactttgc caaagcaggg ctgcaagtgg aattcatcaa ccccatcttc 1020
gagttctcca gggccatgaa tgagctgcaa ctcaatgatg ccgagtttgc cttgctcatt 1080
gctatcagca tcttctctgc agaccggccc aacgtgcagg accagctcca ggtggagagg 1140
ctgcagcaca catatgtgga agccctgcat gcctacgtct ccatccacca tccccatgac 1200
cgactgatgt tcccacggat gctaatgaaa ctggtgagcc tccggaccct gagcagcgtc 1260
cactcagagc aagtgtttgc actgcgtctg caggacaaaa agctcccacc gctgctctct 1320
gagatctggg atgtgcacga atga                                     1344

```

<210> 2

<211> 447

<212> PRT

<213> Homo sapien

<400> 2

Met Ser Leu Trp Leu Gly Ala Pro Val Pro Asp Ile Pro Pro Asp Ser

| | | | |
|-------------------------------------|---------------------------------|-----|-----|
| 1 | 5 | 10 | 15 |
| Ala Val Glu Leu Trp Lys Pro Gly | Ala Gln Asp Ala Ser Ser Gln Ala | | |
| 20 | 25 | 30 | |
| Gln Gly Gly Ser Ser Cys Ile Leu Arg | Glu Glu Ala Arg Met Pro His | | |
| 35 | 40 | 45 | |
| Ser Ala Gly Gly Thr Ala Gly Val Gly | Leu Glu Ala Ala Glu Pro Thr | | |
| 50 | 55 | 60 | |
| Ala Leu Leu Thr Arg Ala Glu Pro Pro | Ser Glu Pro Thr Glu Ile Arg | | |
| 65 | 70 | 75 | 80 |
| Pro Gln Lys Arg Lys Lys Gly Pro Ala | Pro Lys Met Leu Gly Asn Glu | | |
| 85 | 90 | 95 | |
| Leu Cys Ser Val Cys Gly Asp Lys Ala | Ser Gly Phe His Tyr Asn Val | | |
| 100 | 105 | 110 | |
| Leu Ser Cys Glu Gly Cys Lys Gly Phe | Phe Arg Arg Ser Val Ile Lys | | |
| 115 | 120 | 125 | |
| Gly Ala His Tyr Ile Cys His Ser Gly | Gly His Cys Pro Met Asp Thr | | |
| 130 | 135 | 140 | |
| Tyr Met Arg Arg Lys Cys Gln Glu Cys | Arg Leu Arg Lys Cys Arg Gln | | |
| 145 | 150 | 155 | 160 |
| Ala Gly Met Arg Glu Glu Cys Val Leu | Ser Glu Glu Gln Ile Arg Leu | | |
| 165 | 170 | 175 | |
| Lys Lys Leu Lys Arg Gln Glu Glu Glu | Gln Ala His Ala Thr Ser Leu | | |
| 180 | 185 | 190 | |
| Pro Pro Arg Arg Ser Ser Pro Pro Gln | Ile Leu Pro Gln Leu Ser Pro | | |
| 195 | 200 | 205 | |
| Glu Gln Leu Gly Met Ile Glu Lys Leu | Val Ala Ala Gln Gln Gln Cys | | |
| 210 | 215 | 220 | |
| Asn Arg Arg Ser Phe Ser Asp Arg Leu | Arg Val Thr Pro Trp Pro Met | | |
| 225 | 230 | 235 | 240 |
| Ala Pro Asp Pro His Ser Arg Glu Ala | Arg Gln Gln Arg Phe Ala His | | |
| 245 | 250 | 255 | |
| Phe Thr Glu Leu Ala Ile Val Ser Val | Gln Glu Ile Val Asp Phe Ala | | |
| 260 | 265 | 270 | |
| Lys Gln Leu Pro Gly Phe Leu Gln Leu | Ser Arg Glu Asp Gln Ile Ala | | |
| 275 | 280 | 285 | |
| Leu Leu Lys Thr Ser Ala Ile Glu Val | Met Leu Leu Glu Thr Ser Arg | | |
| 290 | 295 | 300 | |
| Arg Tyr Asn Pro Gly Ser Glu Ser Ile | Thr Phe Leu Lys Asp Phe Ser | | |
| 305 | 310 | 315 | 320 |
| Tyr Asn Arg Glu Asp Phe Ala Lys Ala | Gly Leu Gln Val Glu Phe Ile | | |
| 325 | 330 | 335 | |
| Asn Pro Ile Phe Glu Phe Ser Arg Ala | Met Asn Glu Leu Gln Leu Asn | | |
| 340 | 345 | 350 | |
| Asp Ala Glu Phe Ala Leu Leu Ile Ala | Ile Ser Ile Phe Ser Ala Asp | | |
| 355 | 360 | 365 | |
| Arg Pro Asn Val Gln Asp Gln Leu Gln | Val Glu Arg Leu Gln His Thr | | |
| 370 | 375 | 380 | |
| Tyr Val Glu Ala Leu His Ala Tyr Val | Ser Ile His His Pro His Asp | | |
| 385 | 390 | 395 | 400 |
| Arg Leu Met Phe Pro Arg Met Leu Met | Lys Leu Val Ser Leu Arg Thr | | |
| 405 | 410 | 415 | |
| Leu Ser Ser Val His Ser Glu Gln Val | Phe Ala Leu Arg Leu Gln Asp | | |
| 420 | 425 | 430 | |
| Lys Lys Leu Pro Pro Leu Leu Ser Glu | Ile Trp Asp Val His Glu | | |
| 435 | 440 | 445 | |

<210> 3

<211> 1383

<212> DNA

<213> Homo sapien

<400> 3

```

atgtcctctc ctaccacgag ttccctggat acccccctgc ctggaaatgg cccccctcag 60
cctggcgccc cttcttcttc acccactgta aaggaggagg gtccggagcc gtggcccg 120
ggtcgggacc ctgatgtccc aggcactgat gaggccagct cagcctgcag cacagactgg 180
gtcatccacg atcccgaaaga ggaaccagag cgcaagcgaa agaaggggccc agccccgaag 240
atgctggggc acgagctttg ccgtgtctgt ggggacaagg cctccggctt ccactacaac 300
gtgctcagct gcgaaggctg caagggttc ttccggcgca gtgtggtccg tgggtggggc 360
agggcgtatg cctgccgggg tggcggaacc tgccagatgg acgctttcat gcggcgcaag 420
tgccagcagt gccggctgcg caagtgcagg gaggcaggga tgaggggagca gtgcgtcctt 480
tctgaagaac agatccggaa gaagaagatt cggaaacagc agcaggagtc acagtcacag 540
tcgcagtcac ctgtggggcc gcagggcagc agcagctcag cctctggggc tggggcttcc 600
cctggtggat ctgaggcagg cagccagggc tccggggaag gcgagggtgt ccagctaaca 660
gcggctcaag aactaatgat ccagcagttg gtggcgggcc aactgcagtg caacaaacgc 720
tccttctccg accagcccaa agtcacgccc tggcccctgg gcgcagaccc ccagtcccga 780
gatgcccgcg agcaacgctt tgcccacttc acggagctgg ccatcatctc agtccaggag 840
atcgtggact tcgctaagca agtgccctgg ttctctgcagc tgggcccggg ggaccagatc 900
gccctcctga aggcattcac tatcgagatc atgctgctag agacagccag gcgctacaac 960
cacgagacag agtgtatcac cttcttgaag gacttcacct acagcaagga cgacttcac 1020
cgtgcaggcc tgcagggtga gttcatcaac cccatcttcg agttctcgcg ggccatgcgg 1080
cggctggggc tggacgacgc tgagtacgcc ctgctcatcg ccatcaacat cttctcggcc 1140
gaccggccca acgtgcagga gccggggccgc gtggaggcgt tgcagcagcc ctacgtggag 1200
gcgctgctgt cctacacgcg catcaagagg ccgcaggacc agctgcgctt cccgcgcgtg 1260
ctcatgaagc tgggtgagcct gcgcacgctg agctctgtgc actcggagca ggtcttcgcc 1320
ttgcggtcc aggacaagaa gctgccgcct ctgctgtcgg agatctggga cgtccacgag 1380
tga 1383

```

<210> 4

<211> 460

<212> PRT

<213> Homo sapien

<400> 4

```

Met Ser Ser Pro Thr Thr Ser Ser Leu Asp Thr Pro Leu Pro Gly Asn
1      5      10      15
Gly Pro Pro Gln Pro Gly Ala Pro Ser Ser Ser Pro Thr Val Lys Glu
20      25      30
Glu Gly Pro Glu Pro Trp Pro Gly Gly Pro Asp Pro Asp Val Pro Gly
35      40      45
Thr Asp Glu Ala Ser Ser Ala Cys Ser Thr Asp Trp Val Ile Pro Asp
50      55      60
Pro Glu Glu Glu Pro Glu Arg Lys Arg Lys Lys Gly Pro Ala Pro Lys
65      70      75      80
Met Leu Gly His Glu Leu Cys Arg Val Cys Gly Asp Lys Ala Ser Gly
85      90      95
Phe His Tyr Asn Val Leu Ser Cys Glu Gly Cys Lys Gly Phe Phe Arg
100     105     110
Arg Ser Val Val Arg Gly Gly Ala Arg Arg Tyr Ala Cys Arg Gly Gly
115     120     125
Gly Thr Cys Gln Met Asp Ala Phe Met Arg Arg Lys Cys Gln Gln Cys
130     135     140
Arg Leu Arg Lys Cys Lys Glu Ala Gly Met Arg Glu Gln Cys Val Leu
145     150     155     160
Ser Glu Glu Gln Ile Arg Lys Lys Lys Ile Arg Lys Gln Gln Gln Glu
165     170     175
Ser Gln Ser Gln Ser Gln Ser Pro Val Gly Pro Gln Gly Ser Ser Ser
180     185     190

```


Ser Ala Ser Gly Pro Gly Ala Ser Pro Gly Gly Ser Glu Ala Gly Ser
 195 200 205
 Gln Gly Ser Gly Glu Gly Glu Gly Val Gln Leu Thr Ala Ala Gln Glu
 210 215 220
 Leu Met Ile Gln Gln Leu Val Ala Ala Gln Leu Gln Cys Asn Lys Arg
 225 230 235 240
 Ser Phe Ser Asp Gln Pro Lys Val Thr Pro Trp Pro Leu Gly Ala Asp
 245 250 255
 Pro Gln Ser Arg Asp Ala Arg Gln Gln Arg Phe Ala His Phe Thr Glu
 260 265 270
 Leu Ala Ile Ile Ser Val Gln Glu Ile Val Asp Phe Ala Lys Gln Val
 275 280 285
 Pro Gly Phe Leu Gln Leu Gly Arg Glu Asp Gln Ile Ala Leu Leu Lys
 290 295 300
 Ala Ser Thr Ile Glu Ile Met Leu Leu Glu Thr Ala Arg Arg Tyr Asn
 305 310 315 320
 His Glu Thr Glu Cys Ile Thr Phe Leu Lys Asp Phe Thr Tyr Ser Lys
 325 330 335
 Asp Asp Phe His Arg Ala Gly Leu Gln Val Glu Phe Ile Asn Pro Ile
 340 345 350
 Phe Glu Phe Ser Arg Ala Met Arg Arg Leu Gly Leu Asp Asp Ala Glu
 355 360 365
 Tyr Ala Leu Leu Ile Ala Ile Asn Ile Phe Ser Ala Asp Arg Pro Asn
 370 375 380
 Val Gln Glu Pro Gly Arg Val Glu Ala Leu Gln Gln Pro Tyr Val Glu
 385 390 395 400
 Ala Leu Leu Ser Tyr Thr Arg Ile Lys Arg Pro Gln Asp Gln Leu Arg
 405 410 415
 Phe Pro Arg Met Leu Met Lys Leu Val Ser Leu Arg Thr Leu Ser Ser
 420 425 430
 Val His Ser Glu Gln Val Phe Ala Leu Arg Leu Gln Asp Lys Lys Leu
 435 440 445
 Pro Pro Leu Leu Ser Glu Ile Trp Asp Val His Glu
 450 455 460

<210> 5

<211> 25

<212> PRT

<213> Homo sapien

<400> 5

Cys Pro Ser Ser His Ser Ser Leu Thr Glu Arg His Lys Ile Leu His
 1 5 10 15
 Arg Leu Leu Gln Glu Gly Ser Pro Ser
 20 25

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/40440

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/205, 31/195

US CL : 514/555, 562

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/555, 562

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| A | Fowler et al., Liver X receptor Activators Display Anti-Inflammtory Activity in Irritant and Allergic Contact Dermatitis Models: Liver-X-Receptor_Specific Inhibition of Inflammation and primary Cytokine Production., The society for Investigative Dermatology, Inc. October 8, 2002, Pages 246-255. | 1-14 |

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

08 March 2005 (08.03.2005)

Date of mailing of the international search report

26 APR 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Vickie Kim

Telephone No. 571-272-1600

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/40440

Continuation of B. FIELDS SEARCHED Item 3:

CAS/STN ONLINE, CAPLUS, REGISTRY, USPATFUL

structure searched and term searched:LXR agonist, asthma, IL_13overproduction, eosinophilia, rhinitis, allergy, etc